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ABSTRACT
MOLECULAR CLONING and CHARACTERIZATION OF THE COMMON lb 
SUBTYPE OF HCV FROM TURKEY 
Ash Oztan
MSc. in Molecular Biology and Genetics 
Supervisor: Prof. Mehmet Öztürk 
July 1999
Hepatitis C Virus is a major cause o f acute and chronic hepatitis worldwide. 80-90% of 
Hepatitis C Virus infections become chronic and 75% of these cases lead to liver disease, 
including cirrhosis, liver failure and hepatocellular carcinoma. Hepatitis C Virus was first 
identified by molecular cloning o f the viral genome in 1989. Hepatitis C Virus is an 
enveloped virus containing a positive stranded RNA genome with a size o f around 9.5 
kilobases. In terms of genomic organization, it was accepted as a member of Flaviviridae 
family as a new genus named Hepaciviruses. The single-stranded RNA genome encodes a 
single open reading frame, which is transcribed into a single polypeptide o f 3010 or 3030 
amino acids and cleaved into viral proteins Core, E l, E2/p7, NS2, NS3, NS4A, NS4B, 
NS5A, NS5B by host and viral proteases. Sequencing, serotyping and RFLP studies 
indicate that Hepatitis C Virus genome is highly variable. There are six distinct genotypes 
and at least 74 subtypes with different distributions between the geographic areas. 
Variability is not equally distributed throughout the genome. 5' UTR, some parts of the 3' 
UTR and capsid protein are the most conserved regions. The predominant genotype in the 
Turkish population was found to be lb by sequencing of the 5-UTR. In this study, the 
entire sequence encompassing the complete coding region and partial non coding regions 
o f the genotype lb obtained from a HCV-infected Turkish patient was cloned to 
investigate its evolutionary relationship with other genotypes and to study its overall 
genome organization,. In order to characterize the viral genome, viral RNA was extracted 
from the serum, cDNA was synthesized, the HCV genome was amplified by PCR in 7 
overlapping fragments, PCR fragments were cloned into bacterial vectors and cloned 
inserts were sequenced by automated sequencing methodology. The partial sequence data 
covering 70% of the cloned HCV genome indicate that the Turkish lb genotype displays 
high homology to other lb genotypes, but differs from others by distinct amino acid 
changes. To our knowledge, this is the first report about the HCV genome structure from 
Turkey. The HCV subgenomic fragments obtained here will serve to further molecular and 
immunologic studies on this dominant form of HCV found in Turkish patients.
Key Words: Hepatitis C Virus; lb; genome; cloning, sequencing; Turkish Isolate.
Ill
ÖZET
TÜRKİYE DE BASKIN OLARAK GÖRÜNEN HEPATİT C VİRÜSÜ Ib ALT 
TİPİNİN MOLEKÜLER KLONLANMASI VE KARAKTERİZ AS YONU
Aslı Öztan
Moleküler Biyoloji ve Genetik Yüksek Lisans 
Tez Yöneticisi: Prof. Mehmet Öztük 
Temmuz 1999
Hepatit C Virüsü dünyada akut ve kronik hepatitin en önemli nedenidir. Hepatit C Virüsü 
enfeksiyonlarinin yüzde 80 ile yüzde 90 gibi bir oranı kronikleşir ve buna bağlı olarak 
siroz, karaciğer yetmezliği ve karaciğer kanseri gibi hastalıklara sebep olur. Hepatit C 
Virüsü ilk defa 1989 yılında örtüşen bir çok kopya DNA'nın klonlanması ile bulunmuştur. 
Bu zarflı, pozitif tek iplikli RNA virüsü 9.5 kilobazlık bir genoma sahiptir. Genom 
organizasyonuna göre HCV Flaviviridae virüs ailesinin altında Hepasivirusler diye 
adlandırılan yeni bir generada sınıflandırılmıştır. Virüsün tek iplikli RNA genomu 3010 ile 
3030 amino asitten oluşan tek bir polypeptid sentezleyen açık okuma çerçevesi içerir ve 
viral ya da hücre proteazları tarafından Core, E l, E2/p7, NS2, NS3, NS4A, NS4B, NS5A 
ve NS5B virüs proteinlerine parçalanır. Dizi analizi, serotipleme ve RFLP metodları ile 
virüs genomunun çok sayıda değişime uğradığı anlaşılmıştır. Şimdiye kadar farklı coğrafi 
alanlara yayılmış 6 değişik genotip ile 74 civarında altip bulunmuştur. Virüs genomunun 
dizisinde gözlemlenen hızlı değişim genomun tüm bölgelerine eşit şekilde dağılmamıştır. 5'- 
UTR, 3'-UTR’ın bir kısmı ve kapsid proteini en çok korunan bölgelerdir. Türk 
popülasyonunda en çok rastlanan genotip 5' UTR dizi analizinin yapılması ile Ib olarak 
saptanmıştır. Bu çalışmada da ilk Türk HCV izolatının karakterize edilmesi ve virüsün 
evriminin incelenmesi amacı ile bir Türk hastadan izole edilen Hepatit C Virüsü genomu 
klonlanmış ve dizi analizi yapılmıştır. İzlenen yöntemler virüs RNA sının hastanın 
serumundan izole edilmesi, kopya DNA nm sentezlenmesi, genomun örtüşen 7 tane 
polimeraz zincir reaksiyonu ile çoğaltılması, bu fragmentların bakteri plasmidlerine 
klonlanması ve klonlanan bölgelerin otomatik dizi analizi yöntemi ile analiz edilmesidir. 
Klonlamış HCV genomunun %70 lik dizi verisine göre, Türk Ib genotipinin diğer Ib 
genotipleriyle homolojisi yüksek olmakla birlikte, bazi amino asit farklılıkları da 
belirlenmiştir. Elimizdeki verilere göre, bu çalışma Türkiye’den HCV genomu yapısıyla 
ilgili ilk rapordur. Burada elde edilen HCV alt genom parçaları ileride Türkiye’de baskın 
olan bu alt tür ile ilgili moleküler ve immünolojik çalışmalarda kullanılabilecektir.
Anahtar Kelimeler: Hepatit C Virüsü; Ib; genome; klonlama; sekanslama; Türkiye izolatı.
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1. INTRODUCTION
Hepatitis C Vims is a major cause o f non-A, non-B hepatitis worldwide. In 
80-90% o f the cases, the HCV infections become chronic hepatitis which may lead to 
cirrhosis, liver failure and hepatocellular carcinoma (Caselmann et al., 1996). HCV 
infection is typically mild in its early stages and rarely recognized until it has caused 
significant damage to the liver. The cycle o f disease from infection to significant liver 
damage can take 20 years or more. Known risk factors o f the HCV are mainly 
transfusions of blood and blood products, intravenous dmg usage, parental or sexual 
transmission and needle-stick accidents (Okamoto ei al., 1991a). Since 1990, after 
the introduction o f blood tests for detection o f antibodies against HCV proteins, the 
posttransfusion incidence of HCV has decreased in the developed countries. The risk 
o f transfusion related hepatitis is in the range of 1 in 100,000 units transftised in these 
countries. In developing countries lack o f detection tests for blood donors, multiple 
usage of syringes, low socioeconomic levels and lack o f public education leads to a 
drastic increase in new HCV cases. In Turkey mandatory detection o f antibodies 
against HCV in the blood donors' sera started in 1997. The data based on tests made 
on blood donors in Turkey showed that the 1,5% o f the population is anti-HCV 
positive (Figure 1.1; Thomas et al., 1994). Persistent HCV infection is common in 
transplant recipients. It was reported that HCV is the cause o f chronic hepatitis in 
approximately 10% o f all transplant recipients. Antiviral therapy with interferon-alpha 
is effective in only a minority of transplant patients, and since allografts
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from HCV infected donors are quite efficient in transmitting the virus, great attention 
is paid to the appropriate use of organs from HCV-positive donors. At present, these 
organs should be particularly targeted for patients in emergency need of lifesaving 
heart, liver, or lung transplants (Fishman et al., 1996).
Hepatitis C virus was first identified in 1989 by molecular cloning of the viral 
genome in several overlapping cDNA fragments (Choo ei al., 1989). The virus 
genome is approximately 9.5 kb positive single stranded RNA molecule (Figure 1.2). 
RNA encodes a single polypeptide which is cleaved into structural and non-structural 
proteins by viral and host proteases (Figure 1.3). Genome replication takes place in 
the cytoplasm through an RNA intermediate. In terms o f the presence of a lipid 
envelope, sensitivity to organic solvents, single stranded positive RNA genome, a 
long open reading frame, organization o f the polyprotein and cleavage o f polyprotein 
into several viral proteins, HCV was classified as a member of the Flaviviridae and 
has been placed in a new monotypic genus in this family, named hepaciviruses The 
nucleotide sequence is highly variable, the most divergent isolates sharing only 60% 
nucleotide sequence homology. Variability rate o f the genome was estimated to be 
1.44X10'^ base substitution/site/year. According to this data, theoretically all o f the 
nucleotides may change during 700 years of infection in chimpanzees. However 
variability/stability o f the genome varies by region within the genome. HVRl and 
some regions o f the 3’-UTR were found to be the most variable sites between various 
HCV strains (Simmonds P., 1998). Until today isolates from all over the world have 
been sequenced and a classification system was proposed due to the differences in the 
5’-UTR o f the different HCV groups and a phylogenetic tree was constructed where
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HCV isolates were grouped into 6 equally divergent genotypes and each into 
several subtypes. Main types are numbered 1 to 6 and subtypes have been lettered 
a, b and c in order o f discovery (Simmonds el al., 1993). Besides these clearly 
divergent isolates, there are different variants o f the virus within the same 
individual reflecting the high variability rate of the viral genome. The quasispecies 
are not different enough to be grouped as a separate type or subtype but diverged 
enough to escape from the host’s immune system. Some genotypes o f HCV such 
as la, lb, 2a and 2b have shown a broad worldwide distribution, whereas others 
have been seen in specific geographical areas. Genotype 1 b seems to be the most 
common variant in Japan, 1 a is commonly seen in Europe and United States, and 
type 4 is the predominant genotype in Middle East and Central Africa. Turkey is 
between the regions o f Southern Europe and Middle East, but interestingly the 
predominant genotype o f Turkish population was found to be lb at a frequency 
higher than Japan (Yildiz et al., unpublished data).
1.1 VIRAL GENOME ORGANIZATION
l . I . l  UNriMNSLATED REGIONS
l .I . l .I  5 ’-UJR
Complete 5’ UTR spans the 341 nucleotide region at the 5’ site o f the genome 
(Lee ei al., 1992) but shorter sequences have been detected and reported 
(Okamoto et al., 1990, Choo et al., 1991, Kato et al., 1990). 5’-UTR is the
most conserved region in the genome and used in genotyping studies because o f 
the differences specific to the various types.
F igu re  1.4: Model o f  secondary and tertiary structure o f the HCV IRES 
proposed by Honda et al., 1996.
A large conserved stem-loop structure (Figure 1.4) which acts as the Internal 
Ribosome Entrance Site (1RES; Wang etal., 1993) is present at the proximal part. 
HCV viral genome translation is cap-independent and the 1RES is involved in the 
regulation o f replication and translation (Honda et a l, 1999). 1RES provides a 
structure which is able to direct ribosomes to the AUG codon at position 342 for 
translation initiation. p57 polypyrimidine tract binding protein (PTB; Ali et al., 
1995) and 2 subunits o f eIF3 were found to bind to the HCV 1RES (Buratti et al., 
1998).
3’ end of the HCV genome has a tripartite structure with a conventional 3’ 
end sequence, a poly(U) tract in some isolates and a highly conserved 98 
nucleotide sequence which is called 3'X tail. Poly(U) tract appears to be highly 
heterogenous between different isolates and even within the same infected liver. In 
contrast 3’X tail is highly conserved between two most divergent genotypes la 
and lb except two additional U residues at the end in lb isolates (Tanaka el al., 
1996,'Yamada ei al., 1996). It was reported that this region folds into a stem-loop 
structure and polypyrimidine tract binding protein binds to 3'X tail just like 5’- 
UTR (Ito et al., 1998). These finding indicate that 3’-UTR region might also be 
important in replication like 5'UTR.
1.1.2 STRUCTUML PROTEINS 
1.1.2.1 CORE
L I. 1.2 3 ’-UTR
The first structural protein is the HCV core protein (p22). It does not have 
any N-glycosylation sites. Amino acid sequence was found to be well conserved 
between the different HCV isolates (Bukh et al. 1994), which may reflect the 
importance o f the function o f this protein for the survival o f the virus. Also 
because o f this property core protein can be used for efficient detection of anti 
HCV antibodies (Doom et al 1994).
The core protein is cleaved from the polyprotein by the cellular signal 
peptidase which recognize a specific sequence in the peptide chain. The protein 
then undergoes a complex process o f proteolytic maturation and two main 
different products have been described: C l73 (residues from 1 to 173) and C l91 
(residues from 1 to 191). Core protein products are localized in the cytoplasm but
when the expression of Cl 73 takes place in the absence of C 191, it is translocated 
to the nucleus (Santolini el al 1994).
HCV core protein is thought to be a multifunctional protein. It was shown 
that core protein binds to cellular membranes, RNA molecules and 60S ribosomal 
subunit (Santolini et al., 1994). There is also a domain for binding to HCV El 
protein (Lo et al., 1996). There are some data about the multimerization and 
dimerization ability of the core protein (Santolini et al. 1994). It can be detected in 
viral particles in patients serum by immunoelectron microscopy (Kaito et al., 
1994) and related to the capsid protein C o f flaviviruses (Santolini et al 1994). All 
these data indicate that the core protein is the nucleocapsid protein o f the virus 
and it is involved in the viral assembly. Besides having a role in viral 
encapsulation, it was shown to have a trans-acting regulatory role. It possesses a 
nuclear localization signal and as described previously, some forms o f core protein 
were detected in the nuclei. HCV core protein is involved in the transcriptional
repression o f p53 (Ray et al. 1997) and repression p21 WM'l/Cipl/Sidl promoter
activities (Ray et al 1998), and also trans activates c-myc oncogene (Ray et al. 
1996). Yeast two hybrid library screening studies have identified an interaction 
with the cytoplasmic tail o f Lymphotoxin-P receptor (Matsumoto et al. 1997, 
Chen et al 1997) which is involved in host defense mechanism. Lymphotoxin-P 
receptors are the members o f tumor necrosis factor receptors (TNFR). After the 
identification of Lymphotoxin-P receptor, it was shown that core protein also 
binds to the cytoplasmic domain of TNFR 1 which is another member of the 
TNFR family. This binding enhances TNF-induced apoptosis (Zhu et al., 1998). In 
a recent study a transgenic mice model was used to show that the core protein 
induces hepatocellular carcinoma (Moriya et al 1998).
1.1.2.2 ENVELOPE PROTEINS
Other structural proteins o f HCV are E l and E2 glycoproteins. Molecular 
mass o f E l varies from 28 to 35 kDa depending on the strain and conditions o f 
expression (Ralston et a /.,1993), Between residues 350-390 a stretch of 
hydrophobic amino acids is present, which is thought to act as a transmembrane 
anchor (Heinz et al., 1992). In an immunoprécipitation experiment, the E l protein 
was found to be precipitated by an anti-core antibody in the presence but not in 
the absence o f the core protein, indicating that the E 1 protein can interact with the 
core protein. This interaction is independent o f whether the El and the core genes 
are linked in cis or separated in different DNA constructs for expression. 
Deletion-mapping studies indicate that the carboxy-terminal sequences o f both the 
core and the E l proteins are important for their interaction. Since a small portion 
o f E l sequence is exposed to the cytosolic side of the endoplasmic reticulum, the 
interaction between the core and the E l proteins most likely takes place in the 
endoplasmic reticulum membrane (Lo et al., 1996). Other envelope protein E2, 
gp72 is more heavily glycosylated than E l. It is encoded by E2/p7 and has a 
protein backbone o f 32 kDa (Bradley et al., 1992). Full length gp72 is not 
secreted but remains membrane-associated and there is an ER retention signal in 
the C terminal 29 amino acids (Cocquerel et al., 1998). The C terminal position of 
the E2 protein is not absolutely clear at present. The location o f E2 was predicted 
to be between amino acids 384-729 (Takamizawa et al, 1991). It was reported 
that (Hijikata et al., 1991) the full E2 region does not extend aa 740 and the N 
terminal position of NS2 lies about amino acid 810 (Matsuura et al., 1994).
H)
Therefore residues encoding the predicted structural protein p7 could not be 
detected and its expression status is not known. Comparison o f the available 
E2/p7 sequences revealed the presence of hypervariable regions (Kafo el a i, 
1992) at the N terminal o f the E2 protein. HVRl is one o f these regions and it is 
located at the downstream o f the cleavage site between E l and E2/p7, covering 
30 N terminal residues of the E2/p7 protein (Weiner et al., 1991). It lacks a 
conserved secondary structure and resembles the V3 loop of HIV gpl20 (Weiner 
et al., 1992). Specific antibody reactions were detected against peptides 
corresponding to linear epitopes in V Rl, indicating that the N terminal part o f E2 
region encodes antigenically distant variants, subjected to immune selection 
(Weiner et al., 1992; Lesniewski et al., 1993). The observed hypervariability may 
result from sequential mutations leading to escape mutants (Kato et al., 1993) and 
variability rate is related with the immune pressure. This hypothesis was 
substantiated by the lack of variability in the HVRl in an agammaglobulinémie 
patient over a period of 2.5 years (Kumar et al., 1994). Escape from the host 
immune system by means of mutations in HVRl might be involved in the 
mechanism of persistent infection by HCV, which results in chronic hepatitis and 
hepatocellular carcinoma.
It was observed that E l and E2 form heterodimers which indicates that 
envelope proteins are involved in virus morphogenesis at budding. 
Characterization o f HCV glycoprotein complex formation indicates that a majority 
o f these proteins are misfolded aggregates (Deleersnyder et al.,\991). Analysis o f 
HCV glycoprotein assembly in viral and nonviral expression systems showed 
similar results, which indicates that tendency toward aggregation is not due to the 
expression systems used but it is an intrinsic property o f HCV glycoproteins. It
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was observed that formation o f stable E1-E2 complexes is slow because o f the 
slow folding o f these proteins. In the absence o f E2, E l does not fold properly 
which suggests that E2 plays a chaperon-like role in the folding of El (Michalak et 
al., 1997). In addition, it was shown that ER chaperons like BiP, calnexin and 
calreticulin interact with E l and E2 (Choukhi et a i, 1998). In a relatively recent 
study (Pileri et a i, 1998) it was found that E2 binds human CD81, a tetraspanin 
expressed on various cell types including hepatocytes and B lymphocytes. Binding 
of E2 was mapped to the major extracellular loop of CD81. This observation 
indicates that E2 is involved in virus-host interaction and extremely important in 
understanding viral interactions, cell culture studies and foture vaccination studies.
1.1.3 NON-STRUCTUML PROTEINS
Non-structural proteins of the HCV are located at the C-terminus of the 
genome. They are involved in the viral life cycle in the host cell, rather than being 
a structural component of the mature virion. Cleavages in the nonstructural 
protein region are accomplished by two viral protease activities located within the 
NS2-NS3 region. Cleavage at the NS2-NS3 Junction occurs through an 
intramolecular (cis) mechanism in a zinc-dependent reaction (Hijikata et a/., 1993, 
Grakoui et a/., 1993a). In contrast, cleavages mediated by the NS3 serine protease 
release NS3, NS4A, NS4B, NS5A and NS5B proteins (Grakoui A. c /a /., 1993b).
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HCV NS-2 is a transmembrane protein with a C-terminus located into the 
lumen of the endoplasmic reticulum and N-terminus located in the cytosol. There 
is a proteolytic function mapped to the C-terminus of the protein and it is involved 
in the autocatalytic cleavage of NS2/NS3 region in combination with serine 
protease NS3. Proteolysis at the NS2-NS3 junction was proposed to be catalyzed 
by a zinc protease. This hypothesis was based on observations that the NS2-NS3 
proteolytic activity in \n-vitro transcription/translation assays was inhibited by 
metal chelators such as EDTA and phenanthroline, and stimulated by exogenous 
zinc, but there is no direct structural evidence to support it (Pieroni et al., 1997). 
An alternative to the metalloprotease hypothesis involves cysteine-protease- 
mediated cleavage at the NS2-NS3 site. In a recent study a relation between NS2- 
3 autoproteolysis and phosphorylation o f NS5A was reported. This was supported 
by the loss of phosphorylated form of NS5A upon partial or complete deletion of 
the NS2 region from the HCV polyprotein. Also deletion o f the amino acid 
residues between 810 and 907 of NS2 protein was shown to abolish the 
phosphorylated form o f NS5 A and resulted in an impairment of the autocleavage 
at the junction of NS2/NS3. Site-directed mutagenesis experiments that disrupt 
the NS2-3 autoprotease activity and studies that show the expression of NS2-3 
precursor is suiFicient to restore phosphorylation in trans are the other supports of 
this suggestion. Based on these data, apart form the its protealytic role, NS2 
protein was postulated to be involved in phosphorylation o f the NS5A and 
become on of the most important proteins in HCV life cycle (Liu et a i, 1999).
1.1.3 .1 NON-STRUCTURAL PROTEIN 2 (NS2)
1.1
I. L 3.2 NON-STRUCrURAL PROTEIN 3 (NS3)
HCV NS3 protein is a 70-kDa multifunctional enzyme with three known 
catalytic activities in two different domains. The serine protease function was 
mapped to the N-terminal o f the protein, whereas nucleoside triphosphatase 
(NTPase) (Preugschat el al., 1996) and RNA helicase functions (Kadare el ciL, 
1997) reside in the remaining C-terminal region. The HCV NS3 helicase can 
unwind dsRNA as well as dsDNA and RNA-DNA heteroduplexes in the 3'-to-5' 
direction by using NTP or dNTP as the energy source. The helicase and NTPase 
activities are inhibited in the presence of monovalent cations and NTPase activity 
is enhanced by the presence o f polynucleotides (Tai el al., 1996). Despite the high 
degree o f sequence variability in the genome o f HCV, serine protease domain of 
NS3 protein is highly conserved and carries common serine protease domains, like 
His-1083, Asp-1107 and Ser-1165 residues that form the enzyme catalytic triad at 
the active site o f the protein. Temporal hierarchy in NS3 mediated protein 
cleavage was shown by several transient protein expression studies in cultured 
mammalian cells and in vitro transcription/translation assays (Failla el al., 1995; 
Hahm el al., 1995; Lin and Rice, 1995). The cleavage between NS3 and NS4A is 
the first event in the cascade and occur in cis to produce a'mature noncovalent 
NS3-NS4A complex. Then cleavage at the following junctions occur in trans. The 
difference between the cis- and trans-cleavage sites is the presence of threonine as 
the PI residue in the NS3/NS4A Junction, whereas cysteine in the other junctions 
(Grakoui el al., 1993c). Binding of NS4A and presence of a single Zn'^ atom per 
molecule are the necessary factors for the NS3 proteinase function. Binding o f
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NS4A enhances the trans-cleavage of the protease by stabilizing the protein. There 
are several interaction studies between the cellular proteins and HCV NS3 protein. 
It was observed that NS3 is co-localized with wild type p53 but not with mutant 
p53 in the nucleus, whereas when expressed alone it is localized both in the 
cytoplasm and in the nucleus to the same extend (Ishido el al., 1997). NS3 
suppresses actionomycine D-induced apoptosis (Fujita el al., 1996) through the 
decreased expression o f p53 (Ishido el al., 1997), but interestingly expression of 
p2 |W.u i^  a downstream element o f p53 induced apoptosis, is not effected (Fujita el 
al., 1996). NS3 was also shown to be involved in signal transduction pathway by 
inhibiting and sequestering Protein Kinase A (PKA) activity in a cyclic AMP 
(cAMP)- independent manner (Borowski el al., 1997).
/■  1.3.3 NON-SmUCTURAL PROTEIN 4 (NS4)
The HCV NS4 protein is cleaved into 2 regions NS4A and NS4B, by 
transacting NS3 serine protease. NS4A, as stated before, is the structural 
component of NS3 protease. A 14 amino acid hydrophobic region of NS4A has 
been identified as being sufficient for this protease cofactor function o f the protein 
(Butkiewicz el al., 1996). The P strand in the central domain o f the NS4A 
intercalates into the N-terminal part o f the NS3 proteinase and becomes an 
integral part of the protein. The N-terminal 30 residues of the NS3 proteinase 
form P strand with the neighboring molecules in the absence of NS4A (Kim el al., 
1996, Love at al., 1996). It was also observed that NS4A forms nonionic 
detergent-stable complex with the NS4B-NS5A protein complex through the 
central domain which may indicate that four nonstructural proteins might function
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as a multisubunit protein complex. This protein complex might be involved in the 
replication o f HCV genome in combination with viral RNA-dependent RNA 
polymerase and some possible cellular cofactors (Lin et al., 1997). It was also 
shown that NS4A is involved in the phosphorylation of the central region o f 
NS5A (Asabe et al., 1997).
/■ 1.3.4 NON-STRUCTURAL PROTEIN5 iNS5)
The HCV NS5 region encodes two proteins, NS5A and NS5B. NS5A is a 
phosphoprotein, which exists in differentially phosphorylated forms o f 56 k-Da 
and 58 k-Da (Kaneko e( a l, 1994). When only the NS5A region o f the HCV 
polyprotein is expressed in cultured cells, expression of the 56-kDa product is 
higher than the 58-kDa product, whereas production of 58-kDa protein is 
increased in the presence o f NS4A. Both forms o f the HCV NS5A protein are 
located in the perinuclear membrane fraction (Tanji el al., 1995). In a recent· 
study, it was shown that NS4A-dependent hyperphosphorylation o f NS5a is 
genotype specific. In the presence of NS4A it was observed that HCV-2a NS5A is 
phosphorylated but not hyperphosphorylated and it was not associated with 
NS4A, whereas HCV-lb NS5A is hyperphosphorylated and associated with 
NS4A. These results suggest that different phosphoiylation status of HCV NS5A 
region might reflect different virological features o f these two genotypes (Hirota 
et al., 1999). It was reported that NS5A protein, without its 146 amino-terminal 
amino acids and fused to the DNA-binding domain of GAL4, strongly activates 
transcription in yeast and human hepatoma cells (Kato el al., 1997). Another 
important characteristic of this protein is the presence o f interferon sensitivity
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determining region (ISDR). Like other viral transactivator proteins known to 
repress interferon-induced gene expression, the ISDR in NS5A overlaps one of 
the acidic amino acid regions, putative domains conferring this activity. Presently, 
the only therapeutic approach to hepatitis caused by HCV is long-term treatment 
with a-interferon, alone or in combination with ribavirin (Main et ciL, 1995). 
Patient age, duration of infection, presence o f cirrhosis before the treatment and 
genotype are the factors that influence the response to the treatment. Both la  and 
lb exhibit a high level o f resistance to interferon. This resistance was correlated 
with mutations between amino acid positions 237-276 of NS5A protein (Fukuma 
et al., 1998). ISDR was thought to be involved in IFN mechanism via PKR 
pathway. IFN-induced cellular antiviral response is mediated by Mx proteins, the 
2 ’-5’ oligoadenylate synthetase, RNAse L and PKR. Upon induction by IFN, 
these proteins block viral gene expression at multiple levels. PKR is known to 
phosphorylate the a  subunit of the eukaryotic initiation factor 1 (eIF-2a) and 
leads to cessation o f protein synthesis. Many viruses have evolved mechanisms to 
block PKR activity, such as the PKR kinase inhibitor activity of HIV tat protein. It 
was found that NS5A represses PKR activity through a direct interaction with the 
protein kinase catalytic domain upon binding to PKR (Gale et al., 1998). Recently 
it was reported that NS5A protein represses transcription o f the cell cycle 
regulatory gene p21WAFl, while it activates the human profiferating cell nuclear 
antigen gene in murine fibroblasts and human hepatoma cells. Furthermore, 
introduction of NS5A into murine fibroblasts (NIH3T3) promoted anchorage- 
independent growth and tumor formation in nude mice. According to these data, 
NS5A might exhibit a role in cell growth regulation in addition to the other 
activities (Ghosh et al., 1999).
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The amino acid sequence studies on NS5B have shown that there is a 
homology with the other known RNA-dependent RNA polymerase sequences 
(Miller and Purcell, 1990). A Gly-Asp-Asp sequence motif is characteristic o f 
RNA-dependent RNA polymerases o f positive strand RNA viruses and it is 
present between the residues 2737 and 2739 of the NS5B region of the HCV 
genome. According to this sequence data, NS5B was identified as the region that 
encodes viral polymerase and later this activity was demonstrated in vitro (Chung 
and Kaplan, 1992). In a cell-free system, the RNA-dependent RNA polymerase 
activity of the protein has been demonstrated and, by using the baculovirus 
expression system the functional and biochemical characteristics of the NS5B 
protein were identified (Behrens et ciL, 1996). Another result o f this study was 
about the unspecificity o f the polymerase activity. RNA synthesis was observed 
with unrelated input RNA molecules which suggests that the NS5B protein is 
necessary but not sufficient for the replication of the HCV genome. Some other 
viral or cellular proteins are needed for the polymerase specificity. The localization 
of the NS5B protein was found to be at the perinuclear region in association with 
the nuclear membrane and the endoplasmic reticulum or Golgi complex (Hwang et 
al., 1997). This finding suggests that HCV replication might take place in the 
membrane complex and this is consistent with the replication region of other RNA 
viruses. It has been suggested that, in some isolates, a secondary structure of the 
genomic RN A exists at the region encoding the C terminal part o f the NS4 region. 
This structure formation might serve as an IRES which might be located upstream 
of a common inframe ATG codon and accelerate the replication rate o f the viral 
genomic RNA (Okamoto et al., 1992).
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As a summary, chronic hepatitis C virus (HCV) infection occurs in about 3 
percent o f the world population and is a major cause o f liver disease. HCV 
infection is also associated with cryoglobulinemia, a B lymphocyte proliferative 
disorder (Rice et al., 1999). High incidence o f the virus, direct involvement with 
several liver and some immunologic diseases, lack of a successful therapy or 
vaccine lead to an increasing interest in molecular biology studies on HCV. As an 
RNA virus, the mutation rate of the virus is high and the differences between the 
caused pathologies, immunity levels and the resistance o f some o f the variants to 
IFN therapy show that characterization of the variants is one of the most 
important steps in HCV studies.
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1.2 AIM OF THE STUDY AND STRATEGY
As a rapidly evolving RNA virus, HCV contains several base changes 
throughout the genome. As summarized previously this variability is not evenly 
distributed between the regions. Based on the classification system proposed by 
Simmonds ei al. in 1994, 6 main genotypes and several subtypes were defined. 
The characterization of a predominant genotype in a selected population is 
necessary due to the differences between the pathologies caused , immune 
responses created and responses to the IFN treatment between the genotypes. The 
analysis o f the sequence data will provide information about the molecular biology 
o f the virus, its persistence, treatment, evolution and possible vaccination studies. 
The recent data based on tests made on blood donors in Turkey showed that 1,5% 
o f the population is anti-HCV positive. To date several clinical data about HCV 
status in Turkey were published but the molecular data o f the HCV virus type in 
Turkish population was not stated.
In this study we aimed to characterize a HCV genome isolated 
representing the predominant genotype o f Turkish population. Based on the data 
obtained from a previous study o f genotyping of the HCV in the Turkish 
population, a patient with lb subtype was selected. The viral genome was divided 
into 7 overlapping PCR fragments each corresponding to one or two viral protein 
and amplified. PCR products were cloned into bacterial vectors and sequenced. 
Sequencing data were compared with known lb genomes and differences were 
discussed. The strategy o f the project is summarized below.
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2. MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 Chemicals and Enzymes
All enzymes or reagents were purchased from the sources listed below:
Restriction Enzymes
Ribonucléase A
RNAse Inhibitor
Cloned Pfu Polymerase
dNTPs
IPTG
X-Gal
Gel Extraction Kit
Plasmid Purification Kit
PCR Purification Kit
100 bp plus DNA Marker
1 kb DNA Marker
First Strand cDNA Synthesis Kit
Expand High Fidelity PCR System
pGEM-T Easy Vector System
Ampicilin
MB1 Fermentas and Appligene
Sigma
Promega
Stratagene
MBI Fermentas
Sigma
Sigma
Qiagen
Qiagen
Qiagen
MBI Fermentas 
MBI Fermentas 
MBI Fermentas 
Boehringer Mannheim 
Promega 
Sigma
All other chemicals were purchased from Sigma, Difco or Carlo-Erba. 
Oligodeoxynucleotides were synthesized on a Oligo lOOOM DNA Synthesizer 
(Beckman) in the Molecular Biology and Genetics Department, Bilkent University 
and lontek company, Bursa, Turkey.
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2.1.2 Equipment
The list o f equipment used and their manufacturers is given below.
Automatic Pipettes 
P2 
PIO 
P20 
P200 
PI 000
GeneAmp PCR System 9600 and 2400 
Centrifuges
Biofuge (pico)
Avanti J-25 I 
GS-15 R 
Gel Tanks
Horizontal Minicell 
pH Meter
Spectrophotometer DU 640 
Power Supply PAC 300 
UV Transilluminator
Gilson
Gilson
Rainin, Pipet-plus 
Rainin, Pipet-plus 
Rainin, Pipet-plus 
Perkin Elmer
Heraus Instruments
Beckman
Beckman
E-C Apparatus Corporation 
E-C Apparatus Corporation 
Beckman 
BioRad
BioRad GelDoc 2000
2.1.3 Plastic Disposables
The list o f plastic disposables used and their manufacturers is given below:
Microcentrifuge Tubes 
0.2 ul 
1.5 ul 
2.0 ul
Costar
Petri Dishes 
Syringes
LP
Fefarma
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Filter
Test Tubes 
15 ml 
50 ml
Tips
Filter Tips
Costar
Costar and Nunc
Costar and USA/Scientific Plastics 
Greiner
2.1.4 Bacterial Strain
The bacterial strain used in this study is E.coli FIB 101. The genotype of 
the strain is: thi-1, hsdS20 (rB-, mB ), supE44, recAJS, ara-14, leuB6, proA2, 
lacYl, galK2, rpsL20 (strr), xyl-S, mtl-l
Bacteria were grown in liquid culture in Luria-Bertoni (LB) medium. For 
selective medium ampicillin was used in this study. For long term studies, E.coli 
strains were stored in glycerol in 1/1 ratio, at -70°C.
2.1.5 Solutions and Media
2.1.5.1 General Solutions
EDTA. 0.5 M (stock solution), pFl 8.0
CaCb; IM (stock solution), 50mM (working solution)
IX TAE: 40 mM Tris-Acetate, ImM EDTA (pH 8.0)
IXTBE: 45mM Tris-borate, ImM EDTA (pH 8.0)
EtBr; 10 mg/ml water (stock solution) . 
30 ng/ml (working solution)
1X Gel Loading Buffer: 0.25% bromophenol blue, 0.25% xylene cyanol, 
50% glycerol, ImM EDTA
X-Gal 50 mg/ml, disssolved in N,N -dimethyl-formamide, 
stored at -20°C.
IPTG lOOmM, filter-sterilized and stored at 4°C.
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2. 1.5.2 Sohitiom for KNA Extraction
Guanidium Thiocyanate 
N-Laurylsarosine 
Sodium Acetate
4M, prepared with RNase free ddH20 and stored at 
4°C.
0.5%, prepared with RNase free ddH20 and stored 
at 4°C.
25mM (pH 7.0), prepared with RNase free ddH20 
and stored at 4°C.
2 .1.5.3 SoltUions for Plasmid DNA Isolation:
Solution I
Solution II:
Solution HI: 
Phenol/Chloroform:
50 mM Glucose, 25 mM Tris-Cl, pH 8.0, 10 M 
EDTA
0.2 N NaOH, 1% (wt/vol) SDS 
3 M Potassium Acetate, pH 4.8 
1/1 ratio o f phenol and chloroform.
2.1.5.4 Microbiological Media and AnUbiotic
LB: 1% g bacto-tryptone, 0.5% yeast extract, 1% NaCl. .
LB-Agar: 1% g bacto-tryptone, 0.5% yeast extract, 1% NaCl,
1.5% Agar.
Glycerol Stock Solution: 65% glycerol, 0.1 M MgS04 , 0.025 M Tris-Cl
(pH 8.0).
Ampicillin: 100 mg/ml solution in ddH20, sterilized by filtration
and stored at -20°C (stock solution). 100 ug/ml 
(working solution)
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2.2.1 Patient
A female, 59 years old, Turkish patient from the Gastroenterology 
Department o f Çukurova University in Turkey, who was found to be anti-HCV 
antibody positive with second-generation ELISA test was chosen for complete 
genome sequencing of Hepatitis C Virus. HCV RNA detection with PCR 
amplification was positive and according to the sequencing results o f the 5-UTR, 
the genotype o f the sample was previously identified as subtype lb.
2.2.2 Viral RNA Extraction and cDNA synthesis
Total RNA was extracted from patient's sera by single step guanidium 
thicyanate method (Ausbel et al., 1991) with minor modifications (Wilson et al., 
1995).
RNA was extracted from 300 ul o f serum with the freshly made lysis 
buffer containing guanidine-HSCN and mercaptoethanol in the presence o f an 
RNA carrier; RNA was then recovered by isopropanol precipitation and 
resuspended in 10 ul D EPC-ddH20 and denatured at 90 °C. First strand cDNA . 
was synthesized by First Strand cDNA Synthesis kit (Cataloge# K1612, MBI 
Fermentas). cDNA synthesis was performed on 10 ul resuspended RNA in a 20 ul 
reaction volume by using 0.2 ug of random primer, 40 U o f M-MuLV Reverse 
Transcriptase, 20 U o f Ribonucléase Inhibitor (Promega), and ImM (each) 
deoxyribonucleotide at 37 °C for 1 hr.
2.2.2 Oligonucleotide Synthesis
2.2 METHODS
Two sets o f primers were synthesized for this study. First set for 
amplification reactions and second set for the sequencing reactions. Sequences o f 
the primers used in this study were given in Table 2.1 and Table 2.2.
Oligonucleotides used in PCR were synthesized by Lutfiye Mesci (Bilkent 
University, Department o f Molecular Biology and Genetics), at Oligo lOOOM
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DNA Synthesizer by utilizing cyanoethyl-phosphoramidite chemistry. After 
synthesis oligonucleotides were cleaved and deprotected by UltraFast Cleavage 
and Deprotection Kit (Beckman) and dried by the SpeedVac (Beckman). The 
concentrations o f the oligonucleotides were determined by using 
oligodeoxynucleotide quantification option o f the spectrophotometer. 
Oligonucleotides for the internal regions used in sequencing reactions were 
synthesized by lONTEK Çursa, Turkey).
Table 2.1: PCR Primers
Primer Fragment Region Site Primer Sequence
FI ,F Zeus 5'ÜTR+Core 36 ATCACTCCCCTGTGAGGAAC
CoreR 964 (G/A)GAGCA(G/A)TCGTTCGTGACAT
El F Charon .... .................. 850 CCCGGTTGCTCTTTCTCTATC
E2R 2791 ATGC(A/G)GCCATCTCCCGGTC
NS2F r ........NS2... 273ÎT(C/T)CT(A/G)(C/T)TG(G/T)C(G/A)TTACCACC
NS2R 3449 GT(T/C)TG(T/C)TG(G/A/T)G(A/C)GTAGGCCGT
NS3F NS3 NS3....... 3354 CCGAAGGGGGA(A/G)GGAGAT
NS3R 5326 GCACCCA(G/A)GTGCT(A/C/G)GT(G/A)ACGAC
NS4F t NS4 NS4A+NS4B 5283 ATGCATGTCGGC(T/C)GACCT
NS4R 6329 TG(G/A)AGCCA(G/A)GTCTTGAAGTC
NSSAFr”n S5A .....NS5A....... 6142 TATGTGCCTGAGAGCGACG
NS5AR 7695 (A/G)CG(C/T)AGCAAAGAGTTGCTCA
N SSBFr ' NS5B NS5B 7543 AGCGACGGGTC(T/C)TGGTCTAC
NS5BR 9397 CCTGGAGTG(G/T)TT(A/G)GCTCCC
Table 2.2: Sequencing Primers
Prim er Fragm ent > Region Site Sequence
E2FseqI Charon Envelope 2 159]' TGGCACATCACAGGACTG
NS3Fseql NS3 NS3 3771 CGGCGGGGCGACAGCAGGG
NS4Rseql 1.....NS4" ■ ' NS4A + NS4B 5875 CACCTTCCCAAGGCCTAT
NSSAfseql NS5A NS5A 6627 GTGGGGGATTTCCACTACG
NSSArseql [ NS5A NS5A 7294 TCTTCCTCCGTGGAGGT
NSSBfseql NS5B NS5B 8014 TGGCAAAAAATGAGGTTTTCTG
NSSBRseql
1 .
NS5B 8888" TAGGGCTTTCTCAAGTTGCT
T7 Vector Forward Primer, - TAATACGACTCACTATAGGG
M13 Vector
jvj.ujrijpjc
Reverse Primer, 
Multiple Cloning Site
- CAGGAAACAGCTÀTGAC
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HCV genome was amplified in 7 overlapping PCR fragments. Primer sets 
for each fragment were designed from the most conserved regions in the desired 
area. Alignments o f the regions that the primers were designed from were given in 
Appendix A.
Due to the insufficient amount o f template DNA, two PCR reactions with 
the same primer sets were set up for each fragment. Fragments smaller than 1 kb 
were amplified with Cloned Pfu DNA Polymerase (Catalog# 600153, Stratagene) 
in the first round in order to decrease the mutation rate and in the second round 
Expand High Fidelity PCR System (Catalog# 1732650, Boehringer Mannheim) 
was used to obtain PCR products with A nucleotide overhangs. Fragments larger 
than 1 kb were amplified with Expand High Fidelity System in both PCR cycles. 
Optimized PCR reaction conditions for fragments smaller than 1 kb and larger 
than 1 kb are given in Table 2.3 and 2.4 respectively. Amplifications o f all 
fragments were performed as hot start PCR.
2.2.4 Polymerase Chain Reaction
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Table 2.3: PCR Conditions for Fragments Smaller than 1 kb. 
Fragment r ‘ PCR Mix 2"''PCR Mix
Zeus
NS2
• 14 o f the total cDNA 
I ·  50 pmol/ul primer 
>  I X / >  Buffer 
; ·  10 mM dNTP 
! ·  2,5 u n i t s /^ r
• 14 o f the total cDNA
• lOOpmol/ul primer
•  IX P ^ /B u ffe r
• lO m M dN TP
• 1% DMSO
• 2,5 units/y?/
• 1/5 of the f  PCR 
product
• 50 pmolAil primer
• 5X Buffer with MgCi
• 10 mM dNTP
• 2 units Expand High 
Fidelity PCR Enzyme
• 1/5 of the f  PCR 
product
• 1 OOpmol/ul primer
• 5X Buffer with MgCi
• 10 mM dNTP
• 2 units Expand High 
Fidelity PCR Enzyme
PCR Conditions
94 “C 3’
94 "C 30”  
6 0 “C 50” 
7 2 ^ 1 ’
72 °C 10’
30
cycles
94 “C 3’
94 °C 30’ 
6 0 °C 50’ 
72 “C r
72 "C 10’
30
cycles
Table 2.4: PCR Conditions for Fragments Longer than 1 kb.
Fragment 1** PCR Mix
Charon ) ·  14 o f the total cDN A
NS3 ! ·  50 pmol/ul primer 
; ^5X Buffer with MgCi
NS4
' ·  10 mM dNTP
i
NS5A
1
i ·  2 units Expand High
NS5B
i
Fidelity PCR Enzyme
2"** PCR Mix
• 1/5 o f the f  PCR 
product
•50 pmolAil primer 
•5X Buffer with MgCi
• 10 mM dNTP
• 2 units Expand High 
Fidelity PCR Enzyme
PCR Conditions
94 “C 3 ’
94 "C 30”  
60 ”C 50”  
72 X  T
72 T  10’
30
cycles
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2.2.5 Agarose Gel Electrophoresis o f DNA Fragments
DNA fragments were separated by gel electrophoresis using agarose o f 
1% w/v in IX TAE or TBE buffer (Maniatis et al., 1982). 0.2-0.4 ug EtBr/ml o f 
gel was added to visualize the DNA bands. DNA samples were loaded into the 
wells with IX loading buffer. Electrophoresis was performed by running the gel 
for 1 hour at 100 V. The DNA bands were visualized by illuminating with UV 
light at 302nm and the gels were photographed.
The size and concentration o f the PCR fragments were checked in the 
agarose gel. Bands with the correct size were isolated from the agarose gel slices 
by using QIAquick Gel Extraction Kit (Catalog#: 28106, Qiagen Inc.), according 
to the manufacturers instructions.
2.2.6 Electrophoresis Markers
The length o f DNA fragments were estimated by comparing them to 
known molecular weight standards, which had been run on the same gel. DNA 
markers used in this study were 1 kb DNA Ladder (Catalog# SM0311, MB I 
Fermentas) and 100 bp DNA Ladder Plus (Catalog# SM0321S, MBl Fermentas. 
Sizes o f the fragments are given in Figure 2.1.
A B
Figure 2.1: DNA size markers. Panel A; 100 bp DNA Ladder Plus and Panel B; 
Ikb DNA Ladder.
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Primers for PCR reactions do not contain any linker sites. In order to clone 
the amplified fragments, pGEM®-T Easy Vector System (Cataloge # TM042, 
Promega) was used. The vector map is given in Figure 2.2. pGEM®-T Easy 
Vector is a linearized vector with T overhangs in the multiple cloning site. BsiZl, 
/¿■coRJ, Notl enzyme sites are present at the two sides o f the cloning site and they 
are used to check the presence of an insert with a single restriction enzyme 
reaction. T7 and M13 primer sequences, that are present at the two ends of the 
cloning site, were used for sequencing of the insert. Multiple cloning site of the 
vector is in the middle o f the LacZ gene. Presence o f an insert interrupts gene 
expression and colonies containing insert appears white whereas colonies 
containing religated vectors appear as blue, in the presence o f X-Gal and IPTG. 
Cloning reactions were set up in 10 ul total volume and optimized conditions are 
given in Table 2.5.
2.2.7 Cloning ofPCR Products
Table 2.5: Cloning conditions o f PCR products
Reaction Mix
PCR Products Insert , i)GEM®-T 
Easy Vector
L igase. LigaseBulTer
• ZEllSv 60 ng 15 ng 0.5 u lul
C haron 20 ng 15 ng 0.5 u lul
NS2 60 ng 15 ng 0.5 u lul
: 'NS3 ^ 20 ng 15 ng 0 .5 u lul
: NS4 ; 20 ng 15 ng 0.5 u lul
n s s a ; 20 ng 15 ng 0 5 u lul
NS5B 20 ng 15 ng 0.5 u lul
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---------  ..........1 . . , . . . .™ ! ™ ™ ,/1.1! ;l iíW¿lT7 Pionieiti'? Sohl AVn»I
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CGCGG GCGCG C7ÎAAGCfA r - ^^^Vs ' mí TG
..I|¿actj ¿c<í^  i
ATGAC TTAAG COOCO GCGGACGTCC AGCTG
....JL.■.....JЦ i L _ jv i^ Éi?0Hl > i»teM Sch'l
SF6 Tfífjníe’ipjlon S“/3i5
CATAJ QQGAGfiGCT CCGAACGCGT IGGAf OCATAGGTTQ AGW  TCTAT AGTGTCACCT AAAT . . .  3' 
GTATA CCCT CTCGA GGGT7 GCGCA ACCTA COTAT CGAAC TCAÎA AGATA TCACA G^GGA TITA. . .  5'
i .Î I ,1 ±  I
iX'ch I Í5CI ikJtX'i .»‘♦irrS STÇ rjcrnctli^ f
B
Figure 2.2: A.) pGEM®-T Easy Vector Map and B.) Multiple Cloning Site
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Transformation o f plasmid DNA into E.coli was achieved by using calcium 
chloride method. The following procedure is based on Ausubel ei al. (1991).
Preparation o f Competent Cells: 200 ul o f HBlOl overnight grown culture was 
inoculated into 5 ml LB medium and cells were grown at 37°C, shaking at 200 
rpm to an optical density at 590 nm (OD390) of 0.4. 1.5 ml o f growing cells were 
centrifuged at 13,000 rpm for 1 min and gently resuspended in 500 ul ice-cold 50 
mM CaCl2 and incubated on ice for 30 min.
Transformation: Competent cells were centrifuged at 13.000 rpm for 1 min and 
pellets were suspended with 500 ul ice-cold CaCb. All of the cloning mix (10 ul) 
was mixed with the competent cells and incubated on ice for 30 min. The 
competent cells were heat shocked at 42°C for 90 seconds and then incubated on 
ice for 2 minutes. 1 ml o f LB medium was added onto the competent cells and 
incubated at 39°C water bath for 1 hour to allow the expression o f antibiotic 
resistance gene before plating onto the selective LB-Agar plates. After incubation 
cells were centrifuged for 2 minutes and pellet was resuspended in 100 ul left 
supernatant and plated onto LB-Agar plates containing lOOug/ml ampicillin, 
50mg/ml X-Gal, and lOOmM IPTG. Plates were incubated at 37^C overnight for 
the selection of antibiotic resistant transformants.
2.2.8 Transformation ofE.Coli
2.2.9 Small Scale Preparation o f Plasmid DNA (Mini-Preperation)
The method is based on alkaline lysis method o f the Birnboim and Doly 
(1979). Colonies that appear as white after overnight incubation at 37°C were 
selected and inoculated into 5 ml LB media containing ampicillin. After overnight 
incubation at the 37°C shaker, 1.5 ml o f the bacterial culture was centrifuged at 
13,000 rpm for 1 minute. After discarding the supernatant, cells were resuspended 
in 0.1 ml ice cold solution I and 0.2 ml freshly prepared solution 11, 0.5 ml solution 
111 and 0.5 ml phenol/chloroform were added. The tube was shacked vigorously 
by vortexing 2 minutes and centrifuged 5 minutes at 13,000 rpm. Upper phase that
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contains the plasmid DNA was transferred into a clean tube and 1 ml ice cold 
absolute ethanol was added. The tube was centrifuged for 10 minutes at 13,000 
rpm and supernatant was discarded. The pellet was washed with ice cold 70% 
ethanol, left at room temperature for 15-20 minutes to dry and resuspended in 
20 ul ddH20 containing 10 ug/ml RNase A. Samples were kept at -20°C for long­
term storage.
2.2.10 Restriction Enzyme Digestion o f DNA
• Presence o f the correct size inserts in the mini-preps o f selected colonies, 
were checked with restriction enzyme digestions. Restriction enzyme digestions o f 
DNA were carried out in a total volume o f 10 ul with 5-10 units restriction 
enzyme with IX recommended buffer. Digestion reactions of mini-preps were 
incubated for 1.5 hours at 37°C.
2.2.11 Medium and Maximum Scale Isolation (Midi-Preperation)
Cells were grown in 100 ml ampicillin containing Lb for overnight to 
achieve complete saturation. Plasmid DNA was isolated, by using QIAfilter 
plasmid midi kit (Cataloged 10 12145, Qiagen inc.), according to the 
manufacturer’s instructions. The DNA samples were stored at -20°C.
2.2.12 Quantification o f DNA
Concentrations and purity o f nucleic acids were determined by measuring 
absorbency at 260nm and 280nih in a spectrophotometer (Beckmann Instruments 
Inc., CA, USA). Nucleic acid samples displaying OD260 and OD280 values in the 
range o f 1.8 to 2.0 are regarded as highly pure. A value o f OD26o=1.0 corresponds 
to a concentration o f approximately 50 ug/ul double stranded DNA (Maniatis el 
al., 1982).
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The automated sequencing o f the inserts were carried on an ABI Prism 
310 Sequencer at Bilkent University, Department of Molecular Biology and 
Genetics. To increase the sequencing length. Big Dye'* '^ Terminator Cycle 
Sequencing Ready Rection Kit (Catalog# 4363149, ABI Prism) in combination 
with long capillary o f the 310 Sequencer were used. First sequencing reactions 
were carried out with M13 and T7 universal primers that are present at the two 
ends of the cloning site, on the vector sequence. For the middle sequences internal 
primprs were designed and synthesized according to the outer sequencing data 
obtained from M13 and T7 reactions.
2 . 2 .13 AuíomaledSequencing ofDNA Fragments
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3. RESULTS
3.1 Introduction
Hepatitis C Vims is a major cause o f non-A, non-B hepatitis worldwide. In 
a majority o f patients the vims leads to the development of chronic hepatitis and 
later cirrhosis and hepatocellular carcinoma. Since 1989 several complete or 
nearly complete genomic sequences have been published (Choo e( al., 1989, 1992, 
Inchauspe c /a /., 1991, Ogata ei al., 1991, Okamoto et al., 1991b, Takamizawa i?/ 
al., 1991, Yeh i?/ al., 1997, Rispeter ei al., 1997, Aizaki et al., 1998, Chamberlain 
et al., 1997a, 1997b). Comparison o f the nucleotide and polypeptide amino acid 
sequences o f these isolates revealed considerable heterogeneity which leads to the 
classification of multiple genotypes. According to the results of the genotyping 
studies, the distribution of the genotypes o f the virus was mapped. In a previous 
study the predominant genotype o f Turkey was found to be lb by sequencing the 
5’-UTR region (Yıldız el al., unpublished data). Based on the previous studies 
indicating the high variability rate o f the viral genome, it was decided to clone and 
sequence the full length HCV genome representing the first Turkish isolate. The 
strategy to clone the viral genome was based on 1) Patient selection according to 
the subtype, age and interferon therapy, 2) RNA isolation, 3) cDNA synthesis 
according to previously optimized conditions (Yıldız et al., unpublished data), 4) 
Amplification o f the fragments by PCR, 5) Direct cloning o f the PCR products 
and 6) Sequencing o f the cloned regions.
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Isolate Deflnition Subtype Accession Author
Table 3.1: Isolates o f Submitted HCV lb Complete Genomes
AF054248 HCV HC-J4, pCV-J4L2S 
AF054249 HCV HC-J4, pCV-J4L4S 
AF054247 HCV HC-J4, pCV-J4L6S 
HC:U45476 HCV isolate HD-1
HPCKlR1 HCV clone HCV-Kl-Rl
HPCK1R2 HCV clone HCV-K1-R2
HPCKIR3 HCV clone HCV-K1-R3
H Pf 'K 1S 1 HCV clone HCV-Kl-S1
HPCK1S2 HCV clone HCV-K1-S2
H PCK1 S3 HCV clone HC V-K 1 -S3
lb
lb
lb
lb
lb
lb
lb
lb
lb
lb
AF054248
AF054249
AF054247
U45476
D50480
D50481
D50482
D50483
D50485
D50484
Yanagi,M et al. 
Yanagi,M et al. 
Yanagi.M et al. 
Mueller,H.M. 
EnomotOjN. 
Enomoto,N. 
Enomoto,N. 
Enomoto,N. 
Enomoto,N. 
Enomoto,N.
3.2 Strategy for Amplification of the Viral Genome
Sequences o f the previously published lb  isolates, given in Table 3.1 
were aligned and analyzed. For the possible future expression studies, the viral 
genome was divided into 7 overlapping fragments each corresponding to one 
or two viral proteins, as shown in Figure 3.1. From the desired areas, most 
conserved regions were selected for primer design, and variability problem in 
some o f the desired areas was solved by designing degenerate primers. Aligned 
sequences of the primer regions were given in Appendix.
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In Figures 3.2 and 3.3, agarose gel electrophoresis profiles of PCR products o 
the regions Zeus corresponding to 5’-UTR and Core (Panel A), Charoi 
corresponding to Envelope 1 and Envelope 2 (Panel B), Non-Structural 2 (Panel A) 
Non-Structural 3 (Panel C), Non-Structural 4 including regions o f Non-Structural A A 
and Non-Structural 4B (Panel D) , Non-Structural 5A (Panel E), Non-Structural 5E 
(Panel F) were given.
There were unspecific bands in some of the PCR reactions. In order tc 
eliminate the possibility of cloning wrong insert, PCR products were run on agarose 
gel and bands corresponding to the expected sizes were isolated from the agorose gel 
slices.
.19
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Figure 3.2: Agarose gel electrophoresis o f PCR products. DNA size marker in Panel 
A and C is 100 bp DNA ladder Plus (MBI), DNA size marker in Panel B is 1 kb DNA 
ladder (MBI).
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Figure 3.3: Agarose gel electrophoresis o f PCR products. DNA size marker in Panel 
D, C and F is 100 bp DNA Ladder Plus (MBI).
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3.3 strategy for Cloning of the PCR Products
As the sequence o f the viral isolate was not known exactly, instead o f
designing primers with restriction enzyme sites, purified PCR products having A
overhangs, due to the activity of the Tag polymerase, were cloned into a pGEM*’-T
Easy Vector by Promega. Cloning reactions were optimized for each fragment
according to the data given on Table 2.5 and transformed into HBlOl using CaCl2
methodology. Successful cloning o f an insert in the pGEM*'-T Easy Vectors
interrupts the coding sequence o f beta-galactosidase; recombinant clones can usually
be identified by color screening on indicator plates containing X-Gal and IPTG. On
average 20-30 colonies were selected for each cloning reaction and mini-preps of the
colonies were screened with EcoK\ digestion for all o f the fragments except NS5A.
An internal A’coRI site was detected in the NS5A fragment and the presence of the
correct size insert was detected by No1\ digestion for this fragment. During PCR
amplification Pfu and Expand High Fidelity Enzyme System which contain Tag and
Two DNA polymerases were used. Ffu and Pwo enzymes have proof reading activities
and their mutation rate is lower than Tag DNA polymerase, but in order to check if
the base changes are due to a PCR mistake or not, 2-4 colonies were selected for
sequencing step o f the study. 4 colonies from fragments Zeus, NS3, NS4 and NS5A,
3 colonies from fragments Charon and NS2, 2 colonies frorh fragment NS5A were
positive and selected for large scale plasmid isolation. The clones carrying the right
constructs were setup for lOOmL cultures in LB supplemented with lOOpg/mL
ampicillin, and incubated overnight at 37"C. Plasmid isolation was then carried out
using QIAfilter plasmid midi kit from Qiagen. Selected colonies were screened with
¿ ’coRI and Noil digestion once more for the correct size o f the insert and results of
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the midi-prep or mini-prep digestions are given on Figure 3.4 and 3.5. Size of the 
linearized vector without any insert is 3 kb. Insert sizes are 900 bp for Zeus (Panel A), 
1950 bp for Charon (Panel B), 700 bp for NS2 (Panel C), 1980 bp for NS3 (Panel D), 
1000 bp for NS4 (Panel E), 1500 bp for NS5A (Panel F) and 1800 bp for NS5B 
(Panel G). Extra band on Panel F is probably due to insufficient enzyme digestion and 
corresponds to linear vector with the insert.
4.1
7 10 16 23
3000 bp
I III fill III I If l i i  iWit ■ r I l^ tV.·:
7000 
4000 
3500 
3000 
2500
Vector 
3000 bp
Insert 
1950 bp
Vector 
m t : S M  3000 bp
Insert 
700 bp
C
11 12 18
iyjy Insert 
1980 bp
D
Figure 3.4: Agarose gel electrophoresis results o f restriction enzyme digestion o f 
selected colonies. DNA size marker is 1 kb DNA Ladder (MBI). Numbers on the 
lanes correspond to the colony numbers.
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Figure 3.5: Agarose gel electrophoresis results o f restriction enzyme digestion o f 
selected colonies. DNA size marker is 1 kb DNA Ladder (MBI). Numbers on the 
lanes correspond to the colony numbers.
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The automated sequencing o f the constructs were carried out on an ABl Prism 
310 Sequencer at Bilkent University, Molecular Biology and Genetics Department. In 
the first sequencing reaction M13 and T7 primers from the both sides o f the multiple 
cloning site of the vector pGEM-iy-T Easy vector were used. Using Big Dye^ *^ * 
Terminator Cycle Sequencing Ready Reaction Kit and long capillary of the 310 
Sequencer had enhanced the reading length and sequence quality. At the end of the 
first sequencing reaction fragments Zeus and NS2 were read completely. In order to 
read the sequences in the middle o f long fragments internal primers were designed 
from the data obtained from the sequences read by M13 and T7 primers. At the end of 
these two sets of automated sequencing reactions partial sequence data was collected 
and analyzed by aligning with the previously submitted lb sequences given on Table
3.1. Differences in the sequence data will be confirmed by repeating the sequencing 
reactions with further internal primers to obtain double strand sequencing and by 
sequencing the other selected clones. Effects o f these nucleic acid differences on the 
amino acid sequence were analyzed. RJMA and protein sequences of the Turkish 
isolate o f HCV lb, read by the end o f the sequencing reactions, are given on Figure 
3.6. Base changes that lead to amino acid changes are summarized below and at Table
3.2. Codon and base numbers are according to Turkish HCV tb isolate.
3.4 Sequencing of the Cloned Fragments
46
3.4.1 ZEUS
Length o f the fragment corresponding to 5’UTR and coding region o f the 
Core protein is 881 bp. Sequence o f the full length fragment was analyzed. In 5’-UTR 
there is an insertion o f G residue at the site of 295“' bp. and one base change from C 
to A at the site o f 283“' bp.
There are 10 base differences in the Core region that were not reported before 
and 2 o f them results in amino acid differences. At codon 48, Ala which is a 
hydrophobic amino acid is changed into Pro, an amino acid with a cyclic side chain. 
Second amino acid shift is the base difference at codon 147. Leu, a hydrophobic 
amino acid, is changed into another a hydrophobic amino acid Val. Core is one of the 
most conserved regions in the sequenced part o f the viral genome and both functional 
amino acid changes are specific to Turkish isolate.
3.4.2 CHARON
Total length o f the fragment corresponding to the regions coding for E l, 
e2/p7 is 1854 bp. 5 sequencing reactions were set up for this fragment and only the 
reactions of M13 and T7 primers had worked. 248 bp from the 5’ region and 509 bp 
form the 3’ region of the fragment were analyzed. 23 base differences were observed,
16 o f them are the base changes at conserved regions and 5 of them results in amino 
acid changes. At codon 78 hydrophobic amino acid Ala is present in previously 
submitted HCV lb subtypes, whereas in Turkish HCV lb isolate it is changed into 
acidic amino acid Asp. At codon 462 Asp or Asn is changed in to basic Histidine. 
These differences can be functional at protein level.
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3.4.3 NS2
Length o f the fragment coding N S2 protein is 651 bp. Full length o f the region 
was sequenced by M13 and T7 primers. Sequence data for both strands of the region 
was available and possible changes was confirmed from both strands. 12 base 
differences were detected, 9 o f them are in conserved regions and 8 o f them leads to 
amino acid changes. Leu, a hydrophobic amino acid, became Ser which is a 
hydrophilic amino acid, at codon 37. Hydrophobic Val or He is present at codon 52 
o f other isolates, whereas it is changed into hydrophilic Thr in Turkish HCV lb 
isolate. Another functional amino acid change from one aromatic amino acid Phe into 
a hydrophobic amino acid. Leu is observed at codon 129.
3.4.4 NS3
Fragment encoding NS3 protein is 1902 bp in length. 3 sequencing reactions 
with M13, T7 and an internal forward primer were set up for the NS3 fragment. A 
region corresponding to 1121 bp of the fragment; 843 bp from the 5’ end and 278 bp 
form the 3’ end, were analyzed. 26 base differences were observed, 20 o f them take 
place at conserved residues and 14 o f them results in 13 amino acid changes. 6 of 
theses amino acid changes can be classified as functional changes. He or Val at codon 
71 are hydrophobic and changed into Thr, a hydrophilic molecule. Gly, a hydrophobic 
amino acid, at codons 239 and 237 is changed into basic amino acid Lys. An acidic 
amino acid. Asp at codon 276 is changed into an aromatic one, Tyr. At codon 590 
cyclic amino acid. Pro became a basic amino acid, Arg.
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3.4.5 NS4
The size of the NS4 fragment corresponding to the regions encoding NS4A 
and NS4B is 879 bp. Sequence data o f the fragment except an 16 bp region was 
analyzed. 21 base changes, 16 at conserved residues, 5 at variable regions leading to 
amino acid changes, were detected. As a possible functional difference at codon 35, 
hydrophobic amino acid. Leu is changed into an aromatic amino acid, Phe.
3.4.6 NS5A
The sequence of the full length NS 5 A fragment, except a 10 bp region, was 
analyzed. 48 base changes were detected and 18 o f them lead to 16 amino acid 
changes. 43 o f the base changes are at conserved residues whereas 5 of them are at 
the variable sites. An amino acid change at codon 58 from Pro to Ser leads to a 
change from an amino acid with a cyclic side chain to a hydrophilic one and can be 
important for the protein structure. At codon 107 a hydrophilic amino acid Ser is 
changed into hydrophobic Thr. At codon 123 basic amino acid Arg is changed into 
Pro, a cyclic one and at codon 198, hydrophobic Val became hydrophilic ‘Thr. 
Codons 204 and 255 encompass amino acid changes from hydrophilic Thr to 
hydrophobic lie and vice versa respectively. At codon 309 aromatic Phe is changed 
into hydrophobic Thr. Other hydrophilic to hydrophobic amino acid changes were 
observed at codons 360 and 410, from Thr to Ala and Val to Ala respectively. 
Hydrophilic Ser is changed into cyclic amino acid Pro. As described before, ISDR is 
located in NS5A protein and changes in this region, that were not reported previously, 
might be important in future studies on IFN treatment. As shown in Figure 3.5, the 
green highlighted region which shows the ISDR location in Turkish HCV lb isolate, 
encompasses 4 base changes and two of them effecting the same codon 255, lead to
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a change from hydrophobic He to hydrophilic Thr. After confirming the base change, 
this functional amino acid difference should be analyzed in detail.
3.4.7 NS5B
The length o f the fragment corresponding to the region encoding NS 5 В 
protein is 1784 bp. The sequence data of a 985 bp region, corresponding to 485 bp 
from the 5’ end and 500 bp form the 3’ end, was analyzed. There are 28 base changes 
and 22 o f them are from conserved regions. 11 of them lead to 8 amino acid changes. 
At codon 132, 2 base changes lead to a change from hydrophilic Thr to hydrophobic 
Val. Acidic Glu was changed into Arg due to the difference in 3 of the bases 
corresponding to that region. Codon 146 encompasses a change from basic Lys to 
hydrophobic He. At codon 539, basic Arg is present instead o f acidic Gin .
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Figure 3.6 (See the end of the figure for the legend )
(From 36"’ bp of 5’UTR)
ATCACTCCCCTGTGAGGAACTACTGTCTTCACGCAGAAAGCGTCTAGCCATGG
CGTTAGTATGAGTGTCGTGCAGCCTCCAGGACCCCCCCTCCCGGGAGAgCCAT
agTggTCTGCGGAACCGGTGAGTACACCGGAATTGCCAGGACGACCGGgTCCTT
TCTTGGATCAACCCGCTCAATGCCTGGAGATttgggCGTGCCCCCGCGAGACTGC
TAGCCGAGTAGTGTTGGGTCGCGAAAGGCCTTGTGGTACTGCCTGATAGGGTC
TTGCGAGTGCCCAggGAGGTCTcGGTAgACCGTGCACC—(CORE)—aTGAGCAC
M s
GAATCCTaAACCTCAaaGAAAAACCAAACGTAACACCAACCGCCGGcCACAGGA 
T N P K P Q R  K T K  R N T  N R R  P Q
CGTTAAGTTCCCGGGCGGTGGTCAGAtCGTTGGTGGAGTTtACtTGTTGCCgCGC 
D V K F P  G G G Q I V G G V Y L L P R
AgGGGcCCCAGgtTGGGTGtGCgCCCgACTAgGAAgACtTCCgAgCGgtcgAAACCTc 
R G P R L G V R P T R K T S E R S K  P
GTGgAAgGcGacaACCTATcCCcAaGGcTCGcCAgCCCgAgGGCAgGGCCTGGgCacA 
R G R R Q  P I P K A R Q P E G R  A W A
gCCcgGGTACCCTTGGCCCCTCTATGGCAATGAGGGCTTGGGGTGGGCAGGAT 
Q P G Y P W P  L Y G N E  G L G W A G
GGCTCCTGTCACCCCGTGGCTCTCGGCCTAGTTGGGGCCCCACGGACCCCCGG 
W L L S  P R G S  R P S  W G P T  D P R
CGTAGGTCGCGTAACTTGGGTAAGGTCATCGATACCCTCACATGCGGCTTCGC 
R R  S R N L G  K V I  D T  L T  C G  F
CGACCTCATGGGGTATATTCCGCTIGTCGGCGCCCCCGTGGGGGGCGCTGCCA 
A D L M G Y I  P L V  G A P V  G G  A A
GGGCCCTGGCGCATGGCGTCCGGGTTCTGGAGGACGGCGTGAA1TATGCAAC 
R A L A H G V R  V L E  D G V  N Y A
AGGGAATTTGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCTTTGCTATCTTG 
T G  N L P  G C S  F S I  F L L  A L L S
TCTGACCATCCC1GCTTCCGCT—(El)—TATGAGGTGCGCAACGTGTCCGGGG 
C L T I P A S A---------- Y E V R N V S G
GTACCATGTCACGAACGACTGCTCCAACTCAAGCATsKj TGTATGAGGCAGCG 
A Y H V T  N D C S  N S  S I  V Y  E A A
GACATGATCATGCACACCCCCGGGTGCGTGCCCTGCGTTCGGGAGAACAACTC 
D M  I M H T P  G C V  P C V  R E  N N
CTCCCGCTGCTGGGTgGCGCTCACTCCCACGCTtGCGGCTAGGAATGGCAGCGT 
S S  R C W V A L T  P T L A A  R N G  S
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Figure 3.6 Contd.
CCCCACTACGGCAATACGACGCCATGTCaACTTGCTCGTTGGGGCGGATACCT 
V P T T  A I R R H  V N L L V G A ,  D T
TCTGCTCCGC—(ENVl-2, 1098 bp)—TCAGCGCTGCATGCAATTGGACTCGGGG 
F C S---------------------------------------- S A A C N W T R
AGAGCGTTGTf^ACTTGGAGGACAGGGACAGATCGGAGCTCAGCCCGCTGCTG
G E R C H L E D R D R S E L S P L L
CTGTCTACAACAGAGTGGCAAGTG'ITGCCCTGTTCCTTCACCACCTTGCC < GC 
L S T T E W Q V L P C S F T T  L P
tCTGTCCACTGGTTTGATCCATCTACATCAGAACATCGTGGACGTGCAATACC 
A L S T G  L I  H L H Q  N I V  D V Q Y
TGTACGGTATAGGGTCGGCGGTTGTCTCCTTTGCCATCAAATGGGAGTATATC 
L Y G I G S A  V V S F A I K W E Y I
CTGCTGCTCTTCCTCCTCCTGGCGGACGCGCGAGTCTGCGC'ITGCCTGTGGAT 
L L L F L  L L A D A  R V C A C  L W
GATGCTGCTGATAGCCCAGGCTGAGGCCGCCCTAGAGAACCTGGTGGTCCTCA 
M M L L  I A Q A  E A A L E  N L V V L
ATGCGGCGTCCGTGGCCGGGGCACACGGCATTCTCTCCTTCCTTGTGTTCTTC 
N A A S V A G A H G I  L S F L V F F
TGTGCTGCCTGGTACATCAAGGGCAGGCTGGTGGGTGGGGCGGCATACGCCC 
C A A W Y I  К G R  L V G G A  A Y A
T(,TACGGCGTGTGGCCGCTGCTCCTGCTCCTGCTGGCgTTACCACC(;CGAGCA 
L Y G V  W P  L L  L L L  L A L P  P R A
TAIGCC—(NS2)—ATGGACCGGGAGATGGCTGCATCGTGIGGAGGCGCGGTTT 
Y A-------------  M D R E M A  A S C G G A V
TTGTAGGTCTGGCAATCTTgacCTTGTCACCGCACTATAAAGTGCTCCTAGCAA 
F V G L  A 1  L T L S  P H Y  K V L L A
AGCTCATATGGTGGTCACAGTACTTTATCACCAGGGCCGAGGCGCATÍTCCAA 
K L  I W W S Q Y F  I T R A ^ E A H V Q
GTGTGGACCCCCCCCCTCAACGTTCGGGGGGGCCGCGATGCCATCATCCTCCT 
V W  T P  P L N V  R G G R  D A  I I L
CAC'ITGCGCGGTCCACCCAGAGCTAATCTTTGAAATCACCAAAATTTTGCTCG 
T C A V H P E L I F E I T K Í L L
CCGTGCTCGGTCCGCTCATGGTGCTCCAGGCTGGCATAACCAgAGTGCCGTAC 
A V L G  P L M V  L Q A  G I  T R Y  P Y
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TTTGTGCGCGCTCAGGGCCTCATTCGTGTGTGCATGTTGGTGCGGAAAGÇCGC 
F V R A  Q G L  l R V C M  L V R  K A
TGGGGGTCATTACGTCCAAATGGCCÇTCATGAAGTTGGGCGCCCTGACGGGC 
A G  G H Y V Q M A  L M K L  G A L T G
ACGTACÇTTTATGACCATCTTACTCCACTGCGGGACTGGGCCCACGCGGGCCT 
T Y L Y  D H L T P  L R D W A H  A G
GCGGGACCT GCGGTGGCAGTTGAGCCCGTCATCTTCTCTGACATGGAGACCA 
L . R D  L A V A V  E P V  ( F S  D M  E T
AGGTCATCACCTGGGGGGCAGACACCGCGGCGTGTGGGGACATCATCTTGGG 
K V I  T W G A D T A A C G D I I L
CCTACCCGTCTCCGCCCGAAGGGGGAGGGAGATACttctaggaccggccgatagtctcGaag 
G L  P V S A  R R  G R E I L L G P A D S L E
gggcagggtggcgACTCCTT--(NS3)—GCGCCTATTACGGCCTACTCCCAGCAGACG 
G A G W R L L------------  A P I  T A Y  S Q Q  T
CGGGGCCTACTTGGCTGCATCATCACTAGCCTCACAGGCCGGGATAAGAACCA 
R G L L G C I  I T S L T G R D K N
GGTCGAGGGGGAAGTCCAAGTGGTTTCCACCGcAACCCAGTCTTTCCTAGCGA 
Q V  E G  E V  Q V  V S T A T  Q S F  L A
CCTGCGTCGGCGGCGTGTGTTGGACTGTCTACCATGGCGCCGGCTCAAAGACC 
T C  V G G V C W T V Y H G  A G S  K T
CTAgCTGGCCCAAAAGGACCAAÇCATCCAAATGTACACCAATGTGGACCAGGA 
L A G  P K G  P Ί 1  Q M Y T N V D Q
CCTCGTCGGCTGGCCGGCGCCCCCTGGGGCGCGCTCCTTGACGCCATGCACCT 
D L V G  W P A P P  G A R S L  T P C T
GCGGCAGCTCGGACCTTTACTtGGTCACGAGACATGCCGATGTCATTCCGGTG 
C G S S D L Y L V T R H A D V I  P V
CGCCGGCGGgGCGACAGCAGGGGGAgCCTGCTCTClCCcAGGCCcATCTCCTAT 
R R R G  D S  R G S  L L S P  R P I  S Y
TTAAAGGGTTCTTCGGGTGGsCCACTGCTCTGCCCCTCGGGGCACGCTGTGGG 
L K G S S  G G P L  L C P S  G H A V
CATCTTCCGGGCTGCTGTGTGCACCCGGGGGGTTGCCAAGGCGGTGGACTTTG 
G 1  F R A A V C  T R  G V A  K A  V D F
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TACCCGTTGAGTCcgTGGAAACCACTATGCGGTCTCCGGTCTTCACGGACAACT
V P V E S V E  T T M R  S P V F T  D N
CGTCCCCCCCGGCCGTACCGCAGACATTCCAAGTGGCCCATCTGCACGCTCCC 
S S P P  A V  P Q T  F Q V A H  L H A P
ACTGGCAGCGGTAAGAGCACTAAGGTGCCGGCTGCATAcGCAGCCCAAGGGT 
T G S  G K  S T  K V  P A A Y A  A Q G
ACAAGGTACTCGTCCTGAACCCGTCCGTCGCCGCTACCTTAaaGTTTtGGGCGT
Y K V L  V L N  P S V A A  T L K F R A
ATATGTCCAAAGCACATGGTGTCGAaCCCAACATTAGAACTGGGGTAAGGACC 
Y M S K  A H G V  É P  N I  R T  G V  R T
ÇTTACCACGGGCGCCsgCATTACGTATTCCACCTAcGGCAAGTTCCTTGCTtACG 
V T  T G A G I  T Y  S T Y G K F  L A Y
GcGGTTGCTCTGGA—(NS3, 782bp)—TAGATGC rCACTTCTTGTCCCAGACTAA 
G G C S G---------------------  D A H F  L S Q  T
GCAGGCAGGAGACAACTTCCCCTATCTGGTAGCATACCAGGCTACGGTGTGC 
K Q  A G  D N F P Y L  V A Y Q A  T V C
GCCAGGGCCCAGGCcCCACCTCCATCaTGGGATCAAATGTGGAAGTGcCTCATA 
A R A Q A P  P P  S W D Q M W K C L  1
CGGCTAAAACGTACGCTGCACGGGCCAACgCCCGTG—TATAGGaTGGGAGCC 
R L K  R T L  H G P  T P V 7 Y R M G A
GTCCAAAACGAGGTCAiiCCTCACACACCCCgTAACCAAATACATCATGGCATÔ 
V Q  N E V  N L T H  P V  T K Y  I M A
CATGTCGGCTGACCTGGAGGTCGTCACG—(NS4, 67 bp)—TGGTCATTGTGGGC 
C M  S A D L  E V V  T--------------------  V I V G
AGGATCATCTTGTCCGGGAAGCCGGCAATTATTCCCGACAiGGAAGTTCTtTACC 
R I I L S G K P A I I P D K E V L Y
AGGoGTTCGATGAGATGGAGGAGTGCGCCTCACActTCCCTTACATCGAACAGGG 
Q A F  D E M  E E C A S H F P Y  I E Q
GATGCAACTCGCCGAGCAATTCAAGCAGAAGGCGCTCGGGTTGTTGCAAACAGC 
G M Q L A  E Q F  K Q  K A L  G L  L Q  T
GACCAAGCAAGCGGAGGCCGCTGCTCCCGTGGTGGAGTCCAAGTGGCGGGCCC 
A T  K Q  A E  A A A P  V V  E S  K W R A
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TTGAGACCTTTTGGGCGAAGCACATGTGGAACTTCATiAGCGGGATACAGTACTT 
L E T F W A K H M W N F I S G  I Q Y
AGCAGGCTTGTCCACTCTGCCTGGGAACCCCGCAATAGCATCACTGATGGCATT
L A G L S T L P G N P A I A S L M A
TACAGCCTCTATCACTAGCCCGCTCACCACIGAACACACCCTCCTGTTTAACATC 
F T A S  I T S P L  T T Q H T  L L F N  I
TTGGGGGGATGGGTaGCCGCCCAACTCGCaCCCCCCAGCGCCGCTTC-(NS4, 16bp) 
L G G W  V A  A Q L A P  P S  A A  -----------------
GGCATCGCAGGTGCGGCTGTTGCCAGCATAGGCCTTGGGAAGGTGCTTGTGGAC 
G I A G  A A V A S  I G L  G K V L V D
ATCCTGGCGGGCTATGGAGCGGGGGTGGCAGGCGCGCTCGTGGCCTTCAAGGTC 
I L A  G Y G  A G  V A  G A L  V A F  K V
ATGAGTGGCGAGATGCCCTCTACCGAGGATCTGGTCAACTTACTCCCAGCTATC 
M S G  E M P  S T E  D L  V N L L  P A I
CTCTCTCCTGGTGCCCTGGTCGTCGGAGTCGTGTGCGCAGCAATACTGCGí ÍCGG 
L S P G A L V V G V V C A A I  L R R
CATGTGGGCCCAGGAGAGGGGGCGGTACAATGGATGAACCGGCTGATAGCGTT 
H V G  P G  E G A V Q W M N  R L I  A
CGCTCCACGGGGTAACCACGTTTCCCCCACGCACTAtGTGCCTGAGAGCGACGCT 
F A  P R G N H V S  P T H Y V P  E S D A
GCAGCGCGTGTCACACAGATCCTCTcTAGCCTTACCATCACTCAGCTGCTGAAGA 
A A R V T Q  I L S  S L T I T Q L L  К
GGCTCCACCAGTGGATTAATGAgGACTGCTCCACGCCATGT-------- (NS5A)--------
R L H  Q W I  N E  D C S T  P C----------------------------
tCCGGCTCGTGGCTAAGAGACATCTGGGACTGGATATGCACGGTGTTGTCTGACT 
S G  S W L  R D  I W D W I C  T V L S  D
TC AAGACCTGGCTCC AGTCC AAGCT1CTGCCGCGGTTACÇGGGAGTCCCCTTCT 
F K  T W L Q S  K L  L P  R L  P G V  P F
TCTCATGCCAACGTGGGTATAAGGGAGTCTGGCGCGGAGACGGCATCATGCACA 
F S  C Q R G Y  K G V W R G  D G I  M H
CCACCTGTTCATGTGGCGCACAGATCACCGGACATGTCAAAAACGGTTCCATGA 
T T C S C G A Q I  T G H V K N G S  M
GGATCGTTGGGCC/ AAAACCTGCAGtaACACGTGGCATGGAACATT'IGCcATCAA 
R 1 V G P  K T  C S N T W H  G T F P I
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CGCGTACACCACGGGCCCTTGCACACCCTCCCCAgCGCcAAACTATACTAgGGCG 
N A  Y T T  G P C T  P S  P A P  N Y T R A
CTG—cgGGtgGcCGCAgAGGACTaCGTGGAgGtTACgCOGGTGGGGGATTTCCACT 
L 7 R V A A E  D Y V E V T P V  G D F  H
acgtGacgGG—(NS5 A, 1 Obp)—GACAACGTcAAGTGCCC ATGCC AGGTTCCGGCCCC 
Y V T ------------------------  D N V K C P C  Q V  P A
CGAATTCTTCACAGAAGTGGATGGGGTGCGGCTGCAtAGGTACGCTCCGGCGTG 
P E F  F T  E V D  G V R  L H R Y A  P A
CAAACCCCTCCTACGGGAGGAGGTCACATTCCAGGTCGGGCTCAACCAgTATCT 
C K  P L  L R  E E V T  F Q V G  L N Q Y
GGTCGGGTCGCAGCTTCCGTGTGAGCCCGAçCCGGACGTGACAaçGCTCACcTCC 
L V G S  Q L  P C  E P D  P D V T T L T S
ATGCTCAtCGACCCCTCCCACATCACAGCAGAGACtGCTAAGCGTAGGtTGGCCAG 
M L I D  P S H  I T A E T A K R  R L A
AGGGTCTCCCCCCTCCTTGGCCAGCTCCTCAGCTAGCCAGTTaTCTGCG
R G S P S L A S S A S  Q L S A
ІММШ Ш ШІТССАССАССАССАТОАСТССССАСАСОСТОАССТСАООАО 
L К A T C T T H H D S P D A D L T
a©EMCCTCCTGTGGCGGCAGGAGATGGGCGGAAACATCACCCGCGTGGAGTCt 
i^ A  N L L W R 0> E M G G N__ ï T R V E
líAAGGTAGTAATCCTGGACTCTTTCGACCCGCTTCGAGCGGAGGAGGAc 
K V V I L D S F D P L R A E E D
GAAAGGGAAGTGTCCGTTCCaGCGGAGATCCTGCGGAAATCCAGGAAGATTCCT 
E R E V S V  P A E I L R K S R K  I P
TCAGCGATGCCCGTCTGGGCACGCCCAGATTACAACCCTCCA'ITGCTAGAGTCT 
S A M P V W A R  P D Y N P P  L L  E S
TGGGAGAACCCGGACTACGTCCCTCCAGTGGTACACGGGTGCCCATTGCCACCT 
W E  N P D Y V P  P V V H G C  P L  P P
AC TAAGGCCCC ACC AATACC ACCTCC ACGGAGGAAGAGG GCGGTTGTCCTGAC A 
T K A  P P I P P P  R R K R A V V L T
GAATCCACCGTGTCTTCCGCCCTGGCGGAGCTTGCTACTAAGACCTTCGGTAGC 
E S T  V S S  A L A  E L A T  K T F G S
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TCCGGATCGTCAGCCGTTGACAGCGGCACGGCGACCGCCCCTCCCGACCAGTCC 
S G S  S A V  D S  G T A T  A P P  D Q S
ÇCCGACGACGGCGACGCAGGGTC'iGACGCTGGGTCGTACTCCTCCATGCCCCCC 
P D D G  D A  G S  D A  G S Y S S M P P
CTTGAGGGGGAGCCGGGGGATCCCGATCTCAGCGACGGGTCCTGGTCTACCGTG 
L E G E  P G D P  D L  S D G  S W S  T V
AGCGAGGAggctaGTGAGGACGTCGTlTGCTGC—(NS5B)—TCGATGTCCTACACAT 
S E E A S  E D V V C  C---------------  S M S Y T
GGACAGGCGCCCTGATCACGCCATGCgCtGCGGAGGAGAgCAAGCtgcCCATCAAT 
W T  G A  L I T P  C A A E  E S  K L P I  N
GCGCTGAGCAACTCTTTGCTGCGTCACCATAACATGGTGTACGCCACAACATCC 
A L S N S L  L R H  H N M V Y A T  T S
CGCAGCGCAAGTCAGCGGCAGAAGAAGGTCACCTTTGACAGACTGCAGGTCCTG 
R S A S  Q R  Q K K V T  F D R  L Q V L
GATGACCATTACCGGGACGTGCTTAAGGAGATGAAgGCGAAGGCGTCCACAGTT 
D D H Y R D V  L K E M K A K  A S T V
AAGGCTAAACTTCTATCCGTii'GAAGAAGCCTGCAAGCTGACGCCCCCACACTCG 
K A  K L L  S V E  E A C K  L T  P P  H S
GCCAAGTCTAAATTTGGCTATGGGGCAAAGGACGTCCGGAACCTATCCAGCAaG 
A K S K F  G Y G A  K D V  R N  L S  S K
GCCGTTAACCACATCCGCTCCGTGTGGgAgGACCTGCTGGAAgACaCTGAGACAC 
A V N H I  R S V W E D L L E D T E T
CAATCXjAGACCGTCATCATGGCAaAAAaTGAgGTTTTCTGCGTccAAcCacgaAtfGG 
P I  E T V I M A K N E V F C V Q P R  l
AgGCCgcAAGCCAgcTCGcITAATCGGgTtCCcAgACTTGGGGG-(NS5B,776 bp)-----
G G R K  P A R L  I G F P D L G  --------------------------
gATGACTCACNTctTTTcCATCCTTcTAGTCCAGGAGCAACTTGAGAAAGCCcTAGa 
M T  H ? F S  I L L V Q E  Q L E  K A L
TTGtCAGATcTaCGGGGCTTATTaCTCCaTTgAGCCACTTgAccTACGTCAGATCATT 
D C Q I Y G A Y Y S I E  P L D L R Q  1 I
CAACGACTCCATGGTcTTAGCGCATTCTCACTCCACAGTTACTCTCCAGGTGAGA 
Q R L H G L S  A F S L  H S Y S  P G  E
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Fi2ure 3.6 Contd.
TCAAtagGGTGGCTTCATGCCTCAGGAAACTTGGGGTACCGCCCTTGCGAGTCTG 
I N R V A  S C  L R K  L G V  P P L R V
GAGACATCGGGCCAGAAGTGTCCGCGCTAAGCTACTGTCTCAGGGGGGGAGGG 
W R H R A R S  V R A  K L  L S Q G G  R
CTGCCACATGTGGTAGATACCTCTTCAACTGGGCAGTAAGGACCAAGCTCAAAC 
A A  T C G  R Y L F  N W A V  R T  K L K
TCACTCCAATTCCGGCTGCATCTCGGTTGgACTTG—AN-TGGTT'IGTTGCTGGTT 
L T P  I P A A S  R L D  L-------  W F V A G
ACAGCGGGGGAGACATATATCACAGCCTGTCTCGTGCCCGACCCCGCTGGTTTA 
Y S G  G D  I Y H S  L S R A  R P  R W F
TGTTGTGCCTCtTCCTACTTTCCGTAGGGGTAGGCATCTATCTGCTCCCCAACCG 
M L C  L F L  L S V  G V  G I  Y L  L P  N
ATGA— (3’UTR)-- ACGGGGAGCCAACCACTCCAGG
R *----------------
Figure 3.6: RNA and amino acid sequences of the Turkish isolate of the HCV subtype 
lb. Missing bases are shown with dashes. Numbers and fragment names in the brackets 
correspond to the missing bases in side those fragments.
Underlined bases correspond to the base changes that cause amino acid 
^ffemices^^^
^ re e n  highlighted region :
Yellow highlighted regions : Strating point of fragments.
X ; Base changes on conserved regions, detected only in Turkish HCV isolate.
X : Base changes on variable sites.
Y : Amino acid changes on conserved regions.
Y : Amino acid changes on variable regions.
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(Insertion)
' 4 ^  : G — — — — “ “ — —  , —
C o re 4.50 ■ : 48·· ■' C CG CJCG <3C’G GCG GCG O C G GCG GCG GCG GCG GCG
738 147 t  -HP- V G TG CTG : CTG CTG C TG T T G TTG T TG T l ’G T T G C TG
K! + E 2 26 ■ l/V /lz  A GCG ATA ATA A TA GTG C TG GTG G TG c r o GTG G TG
214 ■ :'72· D N AAC GAC GAC G A C G A T GAT GAT GA T GAT GAC GAT
233 ■ : '^8 A. . GA T G C T GCT G c rr GCT GCT ck : t G CC CK'T <.k : t c k :c
1349 450 N /T /K AGC AAT AAT AAT AAC ACC AAC A A A ACC AAC /Vy\A
1384 462 N/D C AG /VAC AAC AAG GAC OAT G A C XVC OAC AAC
N S2 UO ' 37 , t  ■ 8 t C A TTA TTA TTA TTA T TG TTA T T G TTA TTA TTA
142 48 V GTG ATG ATCt ATG TTG T TG C TG TTG TTG TTG TTG
155 52 vTi: n· ACC G T C GTC G TC ATC ATC ATC A l'C ATC ATC ATC
257 85 1 - V G TG A TA A TA ATA ATA A TA ATA A T A A TA ATA ATA
356 119 i ' V A GCC G TC GTC GTC GTC GTC GTC GTG G TC G TC G TC
38^ 1 129 ■ CTC TTC TTC TTC TTC TTC TTG TTC TTC TTC r r c
418 140 V I, C TT G T T GTT G TT GTT QTC GTC GTC G TC GTT GTT
497 166 V **-1· ■ ATC G TC GTC O TC G TT QTC GTC GTC GTC GTC GTO
NS3 ■ , 212 ■ ::'7I ■' ' T A CC ATC A TC ATC OTC ATC ATC ATC ATC A TC ATC
523 175 ' M C.TG A TG A TG ATO ATG ATG ATO ATO A TG ATG ATG
709 237 : : Q  din. k AAG GOG GGG· G G G GGC 0 0 0 OGC’ GOA GOG OOC GOA
710 237 . Q  K AAC GGG O G G CiGG GGC GOG GGC GO A GOO OOC OGA
715 239 ■ 0  K CGG GGG O G G G G G GOG GOO CtOG GGG OGO OGG GOO
747: 2^19 V> »H· E GAA GAC G A C GAC OAC G A T O AC GAC G A T GAC G AC
775 259 1 V G TT A r r ATT ATT ATC A T C ATC ATG ATC ATC ATC
790 264 s/l> -»,► H OOC T C C TCC TCC C CT C CC CCT < X C CCC CCT C CT
826 276 ■ D  -piv. . y TA C GAC GAC GAC G A C G A C G A T GAT G A C G A T G A T
1769 590 0 .HI*»«, CGT C C T CCT C C T C CT C CT C CT C C T c c r C CT CCT
1792 598 1, V G TG CTO C 'lG C TG C TG C TC C TG C TG C T G C T G C TG
1804 602 h  M A TG C TA C IA CTA C TA CTA C TA C TA C F A C TG C T A
1829 610 i/T  · ►» N AAC A TC ATC ATC ACC A CC ATC ACC A C C A TG A T A
1843 615 j  ■:**·■ V G T A  : ATA A TA ATA ATC A TA ATA ATA A T A A T A A T A
N S4 123 18 . . R AAG AGG AGG AGO AGG AGG A G O A G G AGG AGO A G G
140 24 E  A. GCG GAG GAG GAG GA G GAG G A G GA G GAG GAG GAG
172 35 ■ U V TTC C TT CTT C TT CTC CTC CTT C T C C T C C l’T C TC
548 154 t i  . i»*. A GCC GGG . GGC O G C G G C GGC G G C GGC GGC GGC G d C
799 245 S - ►  P CCA TC G TC G TCG TTC TCG TCG TCG T C G T a 3 T C G
NS5A 22 8 V  i ATC G TT G TT G TT G TT G TT G TC G T l' GTT G TC G TT
172 58 P  1·^ 8 TCA C CA C C A CGA C C A C CA C CA CCC C C A C C A C C G
319 107 i l  ·■ » -  T A C T TCA TC A TC A TCA TCT TCC T C C T C T T C C T C C
351 117 E  .p··» D GAC G A G GAO GAG GA G GA G G A G GA G G A G G A G G A G
368 123 R p»- P GCO C G T COT C G T CGO CGG C G G CGG C G G C G G C G G
579 193 , OAC GAA OAA GAA G A A O A A GA A G A A GAA OAA GAA
592 198 V IP*^  T ACG GTG G TG G TG O TG GTG G TG GTG G TG G TG GTG
593 198 ; V -I ·»  r ACG G TG G TG GTG GTG OTG GTG GTO GTG GTG GTG
611 204 T  IN* T A TC ACC M X ACC AGC A CC ACC ACC ACO ACC ACC
764. ■ 255. ■; 1 ■ #** T ACT ATC ATC ATC ATC ATC ATC ATC ATC ATC ATC
765 255 : r T A c rr A TC ATC ATC ATC ATC ATC ATC ATC ATO ATO
925 309 : P -P*» 1 A TT TTC TTC TTC T l'T T TT TTC T T C TTT T T C T TC
943 315 V. G TG ATA ATA ATA ATA ATA ATA ATA ATA ATA  ^ ATA
945 315  ^ i rpN ' V,;· OTO ATA ATA ATA ATA ATA ATA ATA ATA ATA ATA
991 331 D/A - ·* . N AAG OAC OAC OAC GAC OAC GAC OAC G AC GAC G C C
1078 360 T  Pn  a G CG ACG ACG A a i ACO ACG ACG ACO ACG ACG ACG
1201 401 ff ' -PN P C C C TC C TC C TCC TCC T C C : TC C TG C TCC TCC TCC
1229 410 : H  »N A G C T G TT G TT GTT o r r GTT G T l' GTT G TT G TT O TT
N S5B 391 130 D E GAO GAC G A C GAC G A C GAT G A C GAT G A T G A C G A T
395 132 r  IN- V G TC ACC ACC ACC ACC ACC ACC ACC ACC ACC ACC
396 132 T  -PN V G TC ACC ACC ACC ACC ACC A C C ACC ACC ACC ACC
434 145 B  PN E CGA GAG GA G GAG GAG GAG G A G GyVG GAG GAG GAG
435 145 B PN , R CGA G A G GAG G A G GA G GAG G A G GAG GAG GA G G A G
436 145 B  PN. R CG A  . GAG GAG G A G GA G GAG G A G G A G GAG GAG GAG
439 146 K · !►  I A TT AAG AAG AAG AAA AAA AAG AAA A A A A A G A A A
468 156 : V -PN Cl GGG G T A G TA G TA G TG GTG G TG GTA G TG G TG G I T
1290 130 A IN. V G TC G CT G C T G CT G CC GCC O C G O CT G C C G C G G C T
1617 539 Q  - Pn . R CGG CAG CAG CA G C A G CAG C A G C A G CAG C A G CAG
1715 572 X  .-IN. F TTC CTG C TC GTC CTC CTC C TC C T C CTC CTC CTC
Table 3.2; Summary of codon differences between the HCV lb Turkish isolate 
and other characterized HCV lb genomes. H|: Differences on the conserved 
regions
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4. DISCUSSION
The aim o f this study was to characterize a Hepatitis C Virus genome isolated 
from a Turkish patient by cloning and sequencing the complete genome.
As an RNA virus, HCV genome is highly variable. This is due to the lack o f 
proofreading mechanism o f the RN A polymerase o f the virus that is involved in the 
replication o f the viral genome. The mutation rate throughout the genome differs 
between the regions. The most variable regions are the immunogenic regions so that 
the virus can escape from the immune pressure due to the differences in these sites. 
Soon after the first complete genome sequence of HCV was reported (Choo el al., 
1991) different isolates all around the world were submitted. Several subtypes of 
HCV have been found in different geographic areas (Bukh ei a l, 1993). Today the 
most widely accepted classification of HCV genotypes is that put forward by 
Simmonds ei al. in 1994, which allows the definition of six virus types and a great 
number o f subtypes. The nucleotide sequence identity between types is around 66- 
69% and that between subtypes of the same type 77-80%, whereas an identity of 91 - 
98% is found between sequences of the same virus subtype (Simmonds et al., 1995). 
HCV subtype lb is the predominant genotype found in Turkey. To investigate more 
fully its evolutionary relationship with other genotypes o f HCV and to study its 
overall genome organization, the genome sequence, encompassing the partial coding 
region and non coding regions o f the genotype lb obtained from a HCV infected 
Turkish patient, was determined.
The most important parameter in this study is the reliability o f reported base 
differences. In previously done cloning experiments, many non-functional isolates
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were reported due to PCR mistakes or cloning artifacts. During PCR reactions, DNA 
polymerase enzymes are capable of incorporating wrong bases. Many commercially 
available enzymes have proofreading activity to reduce the PCR base mutation rate. In 
this study a combination o f two enzymes Taq and Pwo DNA Polymerases were used 
as a part o f a commercial PCR kit. Pwo has proof reading activity whereas Taq is 
necessary to increase the fragment length. Using an enzyme with the proofreading 
activity reduced the probability o f a misincorporation considerably but did not 
eliminate the problem completely. Also in a study it was reported that during cloning 
reactions, nonfunctional genomes are selected over functional ones which indicates 
that during replication in the bacteria, mutated fragments are favored (Forns el a i, 
1997). In order to eliminate this problem it was decided to choose more than one 
colony for each fragment. A possible base change that results in an amino acid change 
should be confirmed by sequencing the other colonies o f that region. If same base 
change is reported in the sequences o f other colonies, this increases the chance of a 
real base change rather than a PCR-based mutation or a cloning artifact. The resulting 
sequence represents the predominant genome o f the virus that is present in the 
patient’s serum.
In this study sequence of the 70% of the viral genome is presented. Blast 
search of the available sequences have shown that clones that were sequenced have 
the correct inserts and the viral genome is clearly subtype lb. According to the 
sequencing results given in Figure 3.6, there are total o f 168 base differences and 139 
o f them were on the conserved regions of other sequenced isolates. 63 o f 168 base 
differences cause 56 amino acid changes in the protein sequence. There is only one 
insertion in the 5’-UTR which does not effect the reading frame o f the polyprotein. 
Considering the sequenced portion of the genome, 5’-UTR and Core are regions
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showing the highest homology whereas NS5A encounters most of the base changes. 
In the ISDR there is an amino acid change which may effect the protein structure but 
since the sequence data is not confirmed exactly, the reliability o f the mutation is not 
known. Considering the high mutation rate of the viral genome, a high number of base 
differences were expected but these differences should not interfere with the protein 
function, either by being silent mutations or causing changes to similar amino acids. 
Approximately 64% of the base changes in the sequenced region of the HCV lb 
Turkish isolate do not effect the amino acid sequence and approximately 43% o f the 
amino acid changes are the variations between different types o f amino acids. These 
data increase the possibility that the sequencing data is reliable and the fragments may 
represent a functional viral genome.
5. PERSPECTIVE
At the end o f the first part o f the project, 6652 bases of the 9.5 kb viral 
genome were analyzed. In order to complete the sequences of the missing regions of 
the genome, more internal primers should be designed and sequencing reactions will 
be repeated. According to the sequencing data of this part o f the genome, first 
Turkish isolate o f HCV lb resembles previously submitted HCV lb isolates but 
contains several amino acid changes on the conserved residues o f the 10 clones given 
on Table 3.1. Sequencing the regions with the specific differences should be repeated 
with internal primers and base changes should be confirmed by reading the double 
strand o f the variable regions in order to be sure that the differences are not the 
sequencing artifacts. Also in order to eliminate the PCR artifact probability other
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selected colonies should be sequenced in order to see the same variations. After 
completion of the nucleic acid sequencing and confirmation o f mutations on different 
clones, the exact structure of the Turkish lb genotype will be known. Further studies 
will be needed to test whether the significant mutations are a common future o f 
Turkish lb genotype, rather than changes associated to the isolate that we studied.
If there are specific changes associated to Turkish lb genotypes, such changes 
should be analyzed in terms of viral pathogenecity, immune response and viral 
therapy. As we obtained viral genome fragments each corresponding to a distinct 
protein-coding region o f the virus, these fragments are valuable tools for further 
studies, including but not limited to the production of recombinant proteins as 
candidate antigens for immunodiagnosis and vaccine production. The same fragments 
can also be inserted into mammalian expression vectors to perform molecular studies 
related to different aspects o f virus-associated cellular events, such as the elucidation 
of viral entiy into the host cells, viral replication as well as phenotypic changes in host 
cells some o f which may shed further light onto the suspected role of viral protein in 
malignant transformation o f hepatocytes.
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7. APPENDIX
Alignments o f PCR primer sequences of 10 HCV subtype lb isolates.
FORWARD-1 PRIMER
A F054249
A F054247
A F054248
HCU45476
HPCKIRI
HPCK1R2
HPCK1R3
HPCKISI
HPCK1S2
HPCK1S3
ATCACTCCCCTGTGAGGAACTACTG
CORE REVERSE PRIMER
A F054249
A F054247
A F054248
HCU45476
HPCKIRI
HPCK1R2
HPCK1R3
HPCKISI
HPCK1S2
HPCK1S3
ATGTCACGAACGACTGCTCCAACT
T. . .G
El FORWARD PRIMER
A F054249
A F054247
A F054248
HCU45476
HPCKIRI
HPCK1R2
HPCK1R3
HPCKISI
HPCK1S2
HPCK1S3
CCCGGTTGCTCTTTCTCTATC
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À F 054249  GACCGGGAGATGGCTGCAT
A F 054247 ...............................................
A F 054248  ...............................................
HCU45476 ...............................................
HPCKIRI .................................. C ____
HPCK1R2 ...............................................
HPCK1R3 ...............................................
HPCKISI .................................. C ____
HPCK1S2 ...............................................
HPCK1S3 ...............................................
NS2 FORWARD PRIMER
A F 054249  TCCTACTGGCGTTACCACC
A F054247 ...............................................
A F054248 ...............................................
HCU45476 .... T ____A ........
HPCKIRI  G ...................................
HPCK1R2  G ...................................
HPCK1R3 .T..G...T..........
HPCKISI  G ...................................
HPCK1S2  G ...................................
HPCK1S3 .T..G. ..T..........
E2 REVERSE PRIMER
NS2 REVERSE PRIMER
A F054249
A F054247
A F054248
HCU45476
HPCKIRI
HPCK1R2
HPCK1R3
HPCKISI
HPCK1S2
HPCK1S3
ACGGCCTACTCCCAACAAAC
.........G.T.... G. .
..................G. .
.............. G..G..
...........A .... G. .
..................G. .
...... :...... G. .G. .
..................G. .
NS3 FORWARD PRIMER
A F054249
A F054247
A F054248
HCU45476
HPCKIRI
HPCK1R2
HPCK1R3
HPCKISI
HPCK1S2
HPCK1S3
CCGAAGGGGGAAGGAGAT
...........G ......
...........G ......
...........G ......
...........G ......
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NS3 REVERSE PRIMER
A F054249
A F054247
A F054248
HCU45476
HPCKIRI
HPCK1R2
HPCK1R3
HPCKISI
HPCK1S2
HPCK1S3
GTCGTCACTAGCACCTGGGTGC
........G .............
........C .............
.... T..G.............
....... G .....T .......
........C .............
....... G .............
....... G .....T .......
N54 FORWARD PRIMER
A F 054249  ATGCATGTCGGCTGACCT
A F 054247 .............................................
A F 054248 .............................................
HCU45476 ............. ...............C ............
HPCKIRI .............................................
HPCK1R2 .............................................
HPCK1R3 .............................................
HPCKISI .............................................
HPCK1S2 .............................................
HPCK1S3 .......................A ...................
NS4 REVERSE PRIMER
A F 054249  GACTTCAAGACCTGGCTCCA
A F054247 ..................................................
A F 054248 ..................................................
HCU45476 ..................................................
HPCKIRI ..........................................T . .
HPCK1R2 ..................................................
HPCK1R3 ..................................................
HPCKISI .......................................... T . .
HPCK1S2 .......................... T ....................
HPCK1S3 ............. ....................................
NS5A FORWARD PRIMER
A F054249
A F054247
A F054248
HCU45476
HPCKIRI
HPCK1R2
HPCK1R3
HPCKISI
HPCK1S2
HPCK1S3
TATGTGCCTGAGAGCGACG
74
A F 054249  TGAGCAACTCTTTGCTGCGT
A F 054247 ..................................................
A F 054248  ..................................................
HCU45476  A..C
HPCKIRI ..................................................
HPCK1R2  C
HPCK1R3 ..................................................
HPCKISI ..................................................
HPCK1S2  C
HPCK1S3 ..................................................
NS5B FORWARD PRIMER
A F 054249  AGCGACGGGTCTTGGTCTAC
A F 054247 ..................................................
A F 054248 ..................................................
HCU45476 ..................................................
HPCKIRI ..................................................
HPCK1R2 ..................................................
HPCK1R3 ..................................................
HPCKISI ..................................................
HPCK1S2 ..................................................
HPCK1S3 ...........................C ....................
NS5B REVERSE PRIMER
NS5A REVERSE PRIMER
A F054249
A F054247
A F054248
HCU45476
HPCKIRI
HPCK1R2
HPCK1R3
HPCKISI
HPCK1S2
HPCK1S3
CGGAGCTAACCACTCCAGG
.........A .........
.........A .........
..... C ............
.........A .........
.........A .........
.........A .........
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